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In the Netherlands, approximately 4000 patients are diagnosed with rectal cancer every year1. 
For a long time, the main challenge of rectal cancer was the high rate of local recurrences of 
up to 40%2. The introduction of standardized surgery, i.e. Total Mesorectal Excision (TME)3, 
and preoperative (chemo)radiotherapy4, 5, revolutionized rectal cancer management and 
significantly reduced local recurrence rates to <10%. In the Dutch TME trial, addition of a pre-
operative short course of 5x5 Gray of radiotherapy resulted in a 10-year local recurrence rate of 
5% in the irradiated patients compared to 11% in the patients who were treated with surgery 
only6. Moreover, we learned from the Dutch TME trial that not all patients benefit equally 
from short course radiotherapy; patients with stage I disease showed low local recurrence 
rates regardless of the addition of radiotherapy (0.5 vs 0.7%, p=0.15)5. Patients with locally 
advanced rectal cancer showed a significant decrease in local recurrence with the addition 
of radiotherapy, but the local recurrence rate remained high (19% vs 34%, p<0.001)4. In these 
high risk patients, a short course of radiation will not suffice and better results have been 
shown for long course neoadjuvant combined chemo- and radiation treatment. 
Nowadays, the allocation of neoadjuvant treatment is therefore based on a patient’s a 
priori risk of a local recurrence7. The risk stratification is based on assessment of the most 
important factors for recurrence on MRI. Patients with a low risk are stratified for TME without 
neoadjuvant treatment, patients with an intermediate risk are treated with a short course of 
radiotherapy (5x5 Gy) followed by TME, and the high risk patients will undergo a long course 
of radiotherapy combined with chemotherapy (i.e. chemoradiation or CRT) followed by TME. 
Organ preservation
The primary aim of the CRT is to obtain downsizing or downstaging of the tumor and lymph 
nodes in order to increase the chance of a complete (R0) resection. In approximately 15-
20% of the patients treated with neoadjuvant CRT followed by surgery, no tumor is found 
in the resection specimen8. This means that all tumor cells were destroyed by the CRT, 
which is called a pathological complete response (pCR). Patients with a pCR are known to 
have a better prognosis than patients in whom residual tumor is still present after CRT and 
surgery8. One could wonder whether major surgery is still justified in these patients with a 
pCR, considering that TME is associated with a post-operative complication rate of around 
28%9, the majority of patients requires a temporary or permanent colostomy, and mortality 
rates are 4-12%10. These considerations have led to the introduction of the concept of “organ-
preservation”. An alternative for major resection after CRT in good responders with only a 
small residual tumor (ycT1-2N0) could be a local excision of the tumor remnant by means of 
a Transanal Endoscopic Microsurgery (TEM)11. Another alternative for patients with clinical 
evidence of a complete response (i.e. no evidence of residual tumor or metastatic lymph 
nodes) is to omit surgery completely and instead follow patients intensively; the so called 
‘wait-and-see policy’ or ‘watch-and-wait strategy’. The watch-and-wait strategy was first 
described by the group of Habr-Gama et al.12, 13. They selected clinical complete responders 
(cCR) with digital rectal examination and endoscopy with promising results14. Other groups 
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from the USA, Denmark, and Maastricht have performed the watch-and-wait strategy in 
relatively small series and reported similarly promising results15-18. 
Issues in organ-preservation
The main concern of clinicians with organ-preserving treatments is that the available data is 
insufficient to estimate the oncological safety and there is a potentially increased risk for local 
recurrence and distant metastasis. Ideally, this evidence should be provided by randomized 
trials where eligible patients are randomized between organ-preservation or standard TME. 
However, such trials are very difficult to realize because patients strongly prefer to avoid 
major surgery and a colostomy. Therefore, large prospective registries with long-term follow-
up are required. Furthermore, it is suggested that patients will benefit from a watch-and-wait 
policy in terms of sphincter function and quality of life, but so far only one study showed this 
benefit17. 
Another major issue is the selection of suitable patients for organ-preservation. If the 
assessment of response is not accurate and patients with residual tumor or malignant lymph 
nodes are not identified as such, they will not have radical surgery. These patients will then 
have an increased risk of a local regrowth and potentially a greater risk for distant metastasis 
and impaired overall survival. On the other hand, if a clinical complete response or a very 
good response is not recognized, the options of watch-and-wait or TEM are denied, while 
these might have been good alternatives with less morbidity and mortality. Several strategies 
for the selection of eligible patients for organ-preservation have been reported. 
Currently, published reports mainly use digital rectal examination (DRE) and endoscopy with 
biopsies as tools for the response assessment. However, DRE is known to be an unreliable 
predictor of response19. Endoscopic assessment may overestimate response20, 21 and biopsies 
are often false-negative22, 23. So far, only Maas et al. routinely used MR imaging as an additional 
selection tool17 but the role of imaging in response assessment and patient selection is not 
yet consolidated.
Response assessment after therapy
The value of standard clinical MRI protocols for response assessment is limited with a 
sensitivity of only 49%24. The main problem is the interpretation of post-radiation fibrosis. 
On morphological imaging, fibrosis with or without residual tumor remnants look alike, 
but there is a 50% chance that an area of apparent fibrosis still contains residual tumor25. 
A quantitative approach of morphologic changes, by means of measuring the tumor length 
or volume has been suggested to improve the response assessment. However, different 
methods for measurements and multiple thresholds have been described with variable 
results in often limited numbers of patients. Therefore, its role has not yet been established. 
Functional MR imaging techniques are emerging, which do not look at tumor morphology, but 
target different biological characteristics of the tumor. An intensively investigated technique 
is diffusion-weighted MRI (DWI) with significantly improved accuracies compared to standard 
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MRI, but with limited sensitivity for predicting a complete response26. Another functional MR 
imaging technique that is new on the horizon for cancer imaging is ‘Magnetization Transfer’ 
(MT) imaging, which provides information on the presence of macromolecules within a 
tissue. MT imaging may help us to assess post-radiation fibrosis on a micro-architectural 
level, since fibrosis is rich of collagens and therefore contains may macromolecules27, 28.  
Response prediction before therapy
An interesting concept is to shift the focus towards the prediction of response before the 
onset of therapy. If we could predict early in the treatment process which patients are likely 
to benefit from neoadjuvant treatment and will undergo a good tumor response, this may 
offer new perspectives towards more personalized treatment planning. In the near future, 
this will likely become an increasingly relevant question, since recent and ongoing trials aim 
to extend the indication for neoadjuvant treatment to patients with low-risk tumors with the 
aim of achieving a good response and the options of organ-preservation11, 29. Since these 
patients would not receive neoadjuvant treatment according to the current guidelines, it 
is important to have information on the expected response to neoadjuvant treatment to 
ensure a safe selection of patients that will benefit from such a treatment strategy. Patients 
with a poor response would still require TME, but suffer the consequences of CRT in terms of 
morbidity. 
Preliminary studies have explored the potential role of functional MR techniques such as 
DWI and dynamic contrast-enhanced (DCE) MRI for response prediction. The role of DWI 
is not consolidated yet, since conflicting results have been reported26. DCE-MRI provides 
information on tumor perfusion and vascularization, which is an important factor associated 
with tumor viability and its sensibility to chemo- and radiation treatment30, 31. The evidence 
on DCE-MRI for response prediction to date is limited; some groups reported a high perfusion 
before onset of therapy in good responders32-37, while others found the opposite relation38-40. 
Therefore there is a need for a better understanding of the role of tumor perfusion and its 
relation to response to therapy.
Aims of this thesis
• To evaluate the oncological and functional outcome of organ-preserving treatment 
options after neoadjuvant chemoradiation as an alternative to standard resection
• To explore the role of modern MR imaging techniques to improve patient selection after 
neoadjuvant therapy for organ-preserving treatments
• To investigate the feasibility of a novel MRI technique to predict before onset of treatment 
which patients will show a good response to therapy
General introduction 
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Part I: Organ preservation
Chapter 2 discusses the long-term results of a cohort of 100 patients that was treated with 
organ-preserving treatment options.
Part II: Response assessment after therapy
Chapter 3 reviews the available literature on tumor size and volume measurements on MRI 
for response assessment after chemoradiotherapy. Optimal size and volume cut-offs are 
determined and validated in an independent multicenter cohort.
Chapter 4 explores the potential of the novel MR technique “magnetization transfer” imaging 
to differentiate between residual tumor and fibrosis after neoadjuvant chemoradiotherapy.
In Chapter 5 the clinical applicability of “magnetization transfer” imaging is evaluated to 
differentiate between patients with a good and poor response after neoadjuvant therapy.
Part III: Response prediction before therapy
Chapter 6 focuses on the performance of dynamic contrast enhanced MRI to predict tumor 
response before the onset of neoadjuvant treatment.
In Chapter 7 the mesorectal vasculature before therapy and its relation to tumor response is 
investigated.
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Abstract
Objective
The main aim was to confirm or refute the initially reported promising oncological results in a 
larger cohort of patients with a clinical (near) complete response. Second aim was to update 
the selection and inclusion criteria and to report the long-term functional outcome.
Summary background data 
In patients with locally advanced rectal cancer and clinical complete response (cCR) after 
neoadjuvant chemoradiation, organ-preservation can be considered.
Methods 
Between 2004 and 2014 organ-preservation was offered if response assessment with digital 
rectal examination, endoscopy, and state-of-the-art MRI showed a (near) complete clinical 
response (cCR). Watch-and-wait policy was offered for cCR and three options were offered 
for near cCR: Total mesorectal excision (TME), transanal endoscopic microsurgery (TEM), 
or a second assessment after 3 months. Follow-up included endoscopy and MRI 3-monthly 
during first year, and 6-monthly thereafter. Long-term outcome was assessed with Kaplan-
Meier curves. Functional outcome was assessed two years after inclusion with the Vaizey-
score.
Results
After informed consent 100 patients were included with median follow-up of 37.9 months. 
Sixty-one had cCR at initial response assessment. Thirty-nine had near cCR, of whom 24 
developed a cCR at the second assessment and 15 patients underwent TEM (9 ypT0, 1 ypT1, 
5 ypT2). Fifteen patients developed local regrowth (12 luminal, 3 nodal), all salvageable and 
within 25 months. Five patients developed metastases (3 lung, 1 liver and lung, 1 peritoneal) 
and four patients died. Three-year local regrowth free survival was 84%, distant metastases 
free survival 97%, disease free survival 81%, and overall survival 96%. Mean Vaizey-score was 
significantly better in watch-and-wait patients compared to TEM (3·0 vs 9·7, p=0·002).
Conclusions
Organ-preservation appears oncologically safe for selected rectal cancer patients with a 
cCR after neoadjuvant chemoradiation. Near complete responders can be reassessed after 
3 months or undergo TEM. 
Organ-preservatiOn: lOng term-results
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Introduction
The standard treatment for patients with a locally advanced rectal cancer is neoadjuvant 
chemoradiation followed by total mesorectal excision (TME) after a 6-10 week interval. In 
up to 15-20% of the patients, no residual tumour is found at histopathology1. In 2004, Habr-
Gama et al. suggested that surgery may be omitted in a selected patient group with a clinical 
complete response (cCR)2. Although initially this concept resulted in considerable scepticism, 
there is now an increasing interest in organ-preservation in patients with a clinical complete 
response. Both omission of surgery with a watch-and-wait regimen3-6 and transanal 
endoscopic microsurgery (TEM) of the residual scar7-9 have shown promising outcomes in 
relatively small series. 
In 2011 we reported a pilot study on watch-and-wait (W&W) policy in 21 patients with a 
clinical complete response after neoadjuvant chemoradiation, with an important role for 
MRI in the selection and follow-up of patients4. In this pilot study, the 2-year disease-free 
survival was 89% and the overall survival 100%. As expected, the functional outcomes were 
also better when compared to complete responders that underwent TME. However, the 
number of patients was limited and the mean follow-up was relatively short. Since then we 
have experienced a high interest of both clinicians and patients, and we have continued to 
offer organ-preserving treatment. The selection criteria were slightly widened based on the 
initial favourable experience and TEM was performed for patients with a very good, but not 
complete response. 
The main aim of this study was to confirm or refute the initially promising oncological 
results in a larger cohort of patients with a clinical complete or near complete response after 
neoadjuvant chemoradiation for rectal cancer. Secondary aims were to update the selection 
and inclusion criteria and to report the long-term functional outcome.
Material and Methods
Patient selection
Between 2004 and 2014, patients who were treated with neoadjuvant chemoradiotherapy 
in standard patient care and presented with a clinical complete response at restaging, were 
offered an organ-preserving treatment. Patient were either primarily diagnosed and treated 
in our center or were referred to our center for clinical response assessment and evaluation 
of eligibility for organ-preservation after completion of neoadjuvant treatment in another 
center. Organ-preservation was offered in a prospective cohort study, approved by the local 
IRB and registered in clinicaltrials.gov since 2009 (NCT00939666 and NCT02278653). All 
patients provided informed consent. 
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Table 1. Criteria for a clinical complete response after neoadjuvant therapy. 
- 
- 
- 
- 
- 
‡ Patients had a clinical near complete response if they missed only one or two criteria of a clinical complete 
response, but matched the other criteria for a clinical near complete response. * available since 2006, DRE = 
digital rectal exam; MRI = magnetic resonance imaging
Inclusion criteria were [1] rectal cancer without distant metastasis, [2] neoadjuvant treatment 
(standard chemoradiation of 28x1.8Gy combined with 2x825mg/m2 capecitabine, or 5x5Gy 
with a long interval to surgery), and [3] a clinical complete or near complete response. The 
response was evaluated approximately 8 weeks after completion of neoadjuvant treatment 
with digital rectal examination (DRE), MRI, and endoscopy. Criteria for a clinical complete 
response were described previously4 (table 1). Eligible patients with a clinical complete 
response were offered the watch-and-wait policy as an alternative to standard TME. Patients 
were specifically informed of the experimental nature and the potentially increased risk of 
this alternative treatment in a shared-decision process. Figure 1 represents a typical example 
of the MRI and endoscopic images of a patient eligible for the watch-and-wait policy. Some 
patients had a near complete response at initial response assessment, defined as a very good 
response that did not meet all criteria for a clinical complete response, for example a small 
red lesion at endoscopy, or equivocal lymph nodes on MRI (see table 1). Figure 2 shows an 
example the MRI and endoscopic images of a patient with a near complete response. These 
patients were offered, additional to the standard TME the following two alternative options: 
[1] Transanal Endoscopic Microsurgery (TEM), or [2] postponing the decision between W&W 
and TME until a second assessment after 3 months. Patients that met all the criteria for cCR at 
this second assessment, were offered watch-and-wait. All other patients were referred for TME. 
Organ-preservatiOn: lOng term-results
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Figure 1. Images of a patient with a clinical complete response at the initial response 
assessment. 
Axial (A) and saggital (B) T2-weighted MRI of a distal cT2N0 tumor before treatment (indicated with *) and (C) 
endoscopic image of primary tumor. (D) Axial T2-weighted MRI eight weeks post-chemoradiation, with the white 
arrowhead indicating residual fibrosis. (E) Diffusion-weighted MRI without any high signal, suggesting complete 
response. (F) Endoscopy with a typical white scar (black arrow heads).
Follow-up
Follow-up included the standard follow-up according to national guidelines, with imaging 
of the chest and liver, CEA, and out-patient clinic visits for a period of 5 years. For the organ-
preservation specific follow-up, patients additionally underwent MRI and sigmoidoscopy 
every 3 months during the first year, and every 6 months until 5 years after inclusion4 (See 
Table 2).
Functional outcome
Complications after TEM were recorded and classified according to Dindo et al.10 Patients with 
a follow-up of at least 2 years were approached to participate in a questionnaire to assess the 
presence of faecal incontinence. Functional outcome was measured with the Vaizey score11, 
consisting of 7 questions with a total score ranging between 0 (no incontinence) and 24 
(major incontinence). All scores ≥12 are considered major incontinence.
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Figure 2. Images of a patient with a near complete response at initial assessment and clinical 
complete response after a reassessment 3 months. 
Axial (A) and saggital (B) T2-weighted MRI of distal cT3 tumor (indicated with *)  with evident malignant lymph 
node (white arrow) before treatment and (C) endoscopic image of primary tumor. (D) Axial T2-weighted MRI at 
initial response assessment 16 weeks post-chemoradiation, with the black arrow indicating a residual lymph 
node, potentially malignant. Black arrow heads indicate residual fibrosis. (E) Diffusion-weighted MRI without 
any high signal, suggesting complete response. (F) Endoscopy with a small superficial erythematous ulcer 
(white arrow heads). (G) Axial T2-weighted MRI 3 months later, the lymph node has disappeared. Black arrow 
heads indicate residual fibrosis. (H) Diffusion-weighted MRI without high signal. (I) Typical white scar (white 
arrow heads) visible on endoscopy.
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Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS version 20.0, Inc., Chicago, Illinois, USA). Functional outcome scores were compared 
between W&W and TEM patients with a Mann-Whitney U test. Local regrowth free survival 
(LRFS), distant metastasis free survival (DMFS), disease free survival (DFS) and overall survival 
(OS) were estimated with Kaplan-Meier curves and were compared between different groups 
using the log-rank test.
Local regrowth was defined as tumour regrowth in the lumen or in a local lymph node, 
DMFS as the absence of distant metastases, DFS as the absence of local regrowth, distant 
metastasis, and death from any cause, and OS as the absence of death from any cause. 
Duration of follow-up was calculated from the start of treatment (first day of radiotherapy) to 
the event of interest or the last follow-up date. A p-value ≤0.05 was considered statistically 
significant.
Table 2. Follow-up schedule for patients with organ-preserving therapy
Marked in grey indicates the additional follow-up compared to standard follow-up after total mesorectal 
excision.
CEA = carcinoembryogenic antigen; DRE = digital rectal exam; MRI = magnetic resonance imaging; 
CT = computed tomography
Results
A total of 105 patients was considered for organ-preserving treatment of whom eventually 
100 were included in the programme. Sixty-one patients had a cCR at the first assessment 
and were immediately included in the watch-and-wait policy (W&W). The other 44 patients 
had a near cCR at initial assessment, of whom 15 patients underwent an immediate TEM, 
while the remaining 29 patients underwent a second assessment after 3 months. In the 
15 patients who underwent a TEM, histopathology showed a ypT0 in 9/15 patients (60%), 
ypT1 in one patient (7%), ypT2 in and 5/15 patients (33%). None of the patients with a ypT1 
or ypT2 underwent immediate completion TME. For the 29 patients who were reassessed 
after 3 months, the most common finding of a near complete response at initial response 
assessment was an inconclusive endoscopy such as a small red lesion or ulcer, while MRI 
showed a cCR (11/29, 40%). Other findings were equivocal lymph nodes (5/29, 17%), residual 
high signal on DWI but fibrosis on T2-weighted MRI with cCR at endoscopy (3/29, 10%), 
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residual tumour on T2-weighted but no signal on DWI with cCR at endoscopy (1/29, 3%), 
or near complete response both on endoscopy and MRI (9/29, 31%). Reassessment after 3 
months showed a typical complete response on both MRI and endoscopy in 24 patients, 
who all chose for the watch-and-wait policy and can be considered delayed inclusions. Five 
patients were judged not to have a cCR at this second assessment and were referred for TME: 
one patient had a pCR, the remaining 4 patients had residual tumour remnants. These five 
patients with an incomplete clinical response were excluded from further analyses. See the 
flowchart for details on the selection and inclusion process (figure 3).
Figure 3. Flowchart of patient selection and inclusion. 
TEM = transanal endoscopic microsurgery; W&S = wait-and-see; TME = total mesorectal excision; LR = local 
regrowth; DM = distant metastasis
Overall 100 patients were included for organ-preservation. Sixty-seven patients were male 
(67%) and the mean age was 63.2±10.5 years. Median follow-up was 37.9 months (range 
11.7-119.7), and 52 patients (52%) had a follow-up of at least 3 years. Detailed patient- 
and treatment characteristics are given in table 3. Of the included 100 patients, 24 were 
diagnosed and treated in our center, constituting 17% (24/141) of all patients treated with 
chemoradiation in our center. The remaining 76 included patients were primarily treated in 
another centre and referred to our center specifically for organ-preservation. 
Oncological outcome
Fifteen of the 100 patients treated with an organ-preserving treatment developed a local 
regrowth within the lumen (n=12) or in a lymph node (n=3). All luminal regrowths were 
detected with endoscopy, in four patients it was also visible on MRI (in 3 patients visible on 
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both T2W and DWI, in one patient only on DWI). All lymph node regrowths were detected 
with MRI. All regrowths occurred within 25 months of follow-up. See Figure 4 for MRI and 
endoscopy images of a luminal regrowth after 10 months of follow-up. Figure 5 showes MRI 
and endoscopy images of a nodal regrowth. In two patients with a local regrowth, distant 
metastasis were observed simultaneously, and the treatment was primarily aimed at the 
metastases with a continued control of the local situation. 
Table 3. Patient characteristics
* Adjuvant chemotherapy was offered according to our national guidelines, ^ Pathology after TEM, n.a. = not 
applicable
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Figure 4. Images of a patient included in 
wait-and-see group after initial response 
assessment and who developed a luminal 
regrowth after 10 months of follow-up. 
(A) Axial T2-weighted MRI of primary cT3N1 tumor 
(indicated with *). (B) Endoscopy of primary tumor. 
(C) Axial T2-weighted MRI at initial assessment nine 
weeks after completion of chemoradiation, black 
arrowhead indicates a small fibrotic area. (D) White 
scar at endoscopy typical for cCR. (E) Axial T2-weighted 
MRI after 10 months of follow-up without any sign of 
regrowth. (F) On endoscopy the white scar is still visible 
(black arrowheads), but adjacent there is a nodular 
lesion (white arrowheads). Biopsy showed invasive 
adenocarcinoma and patient was referred for resection 
(ypT2N0).
All but one of 13 isolated local regrowths without synchronous metastasis were detected 
when small and were easily amenable to salvage therapy with a surgical procedure that 
was not more extensive than it would have been originally. One patient required a pelvic 
exenteration for a regrowth after a TEM for a small remaining ypT2 residual anterior lesion. 
At present, all 13 patients remained free of further local recurrence. In addition to the two 
patients with simultaneous local and distant recurrence, three other patients developed 
metastases in lungs, both liver and lung, or peritoneum. Two patients died of metastatic 
disease and two other patients of unrelated causes. Table 4 gives a complete overview of 
all regrowths, distant metastases, and causes of death. The cumulative probability of 3-year 
local regrowth free survival was 84%, distant metastasis free survival 97%, disease free 
survival 81%, and overall survival was 96% (Figure 6).
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Of the 15 patients with a local regrowth, 3 occurred in the TEM-group, all in patients with 
ypT2 residual tumour. The 3-year LRFS for the TEM-group versus the W&W-group was 80% vs 
85% (p=0.60), DMFS and OS were not statistically different between the two groups (Table 5). 
The LRFS for watch-and-wait patients who were included after a second assessment was 
77%, compared to 88% for the patients that were included at the first assessment (p=0.22). 
No significant difference between the two groups was found with regard to DMFS (96% vs 
98%, p=0.73) and OS (96% vs 96%, p=0.95).
Figure 5. Images of a patient with a near complete response who underwent TEM, with 
histopathology showing ypT2 residual tumor. Six months later a nodal regrowth was detected. 
(A) Axial (B) and saggital T2-weighted MRI of primary cT3N2 tumor (indicated with *). (C) Axial T2-weighted MRI 
with black arrowhead indicating malignant lymph node. (D) Axial T2-weighted MRI at initial response assessment 
16 weeks post-chemoradiation, black arrowhead indicates residual fibrosis. (E) Diffusion-weighted MRI with 
focal high signal indicating residual tumor. (F) Endoscopy shows a small residual tumor. Patient was referred 
for TEM and histopathology showed ypT2 tumor. (G) Axial T2-weighted MRI at initial response assessment with 
evident regression of the lymph node. (H) Three months post-TEM the lymph node appear larger. (I) Six months 
post-TEM this was diagnosed as a nodal regrowth. Unfortunately, this patient had simultaneous multiple 
pulmonary metastasis without curative options.
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Table 5. Three-year survival for W&W compared to TEM, and immediate inclusion compared to 
reassessment after 3 months.Table 5. Three-year survival for W&W compared to TEM, and immediate inclusion compared to reassessment after 3 
months. 
 
 Functional outcome
Forty-six patients received the questionnaire of whom 29 completed the questionnaires (22 
W&W, 7 TEM, response rate 63%). The total Vaizey score of W&W-patients (mean 3·4±3·9) was 
significantly better than TEM-patients (mean 9·7±5·1, p=0·003). Patients in the watch-and-
wait policy scored better on three items: incontinence for liquid stool, incontinence for gas, 
and the need for a pad or plug. See figure 7 for detailed results. Only one W&W-patient (1/22, 
5%) suffered from major incontinence (score ≥12) compared to three patients in the TEM 
group (3/7, 43%). All but two TEM-patients (13/15) had post-operative complications, 6 of 
whom with a Dindo classification of II or higher. Most long-term complications were peri-anal 
and abdominal pain (54%).
Figure 6. Local regrowth free survival and overall survival for the total of 100 patients in an 
organ-preserving treatment.
CHAPTER 2
30
Figure 7. Functional outcome based on Vaizey score. A higher score indicates a poorer result.
* Indicates that the difference was statistically significant.
Discussion
The main conclusion is that organ-preserving treatment for (near) complete responders 
after CRT for locally advanced rectal cancer is feasible and results in a high 3-year disease-
free survival of 81% and a high overall survival of 96%. This study suggests that in a careful 
program of organ-preservation there is little or no oncological disadvantage for selected 
patients with a (near) clinical complete response.
There is a legitimate concern that organ-preservation in rectal cancer could negate the 
improvements in oncological outcome that have been achieved by optimal use of a good 
surgical TME technique and (neo)adjuvant treatment. The concern is that the increased 
number of local recurrences will lead to a decreased survival because some may not be 
amenable to salvage therapy and because some may cause metastases later. In the present 
study only one of the hundred patients was disadvantaged by the organ-preservation 
approach because a pelvic exenteration was required to control the local regrowth. This 
occurred after a TEM for a ypT2 tumour, where we now strongly recommend immediate 
completion surgery. We have not yet seen an unresectable local regrowth, and encountered 
only one local recurrence after salvage TEM and no local recurrence after salvage TME surgery. 
In two patients with a local regrowth, systemic disease was diagnosed simultaneously, and 
there were no patients with systemic disease diagnosed after the local regrowth. Given this 
timeframe, it is unlikely that the regrowth was the source of the metastases, although follow-
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up after local regrowth is relatively short in the majority of the patients (Table 3) Even more, 
three patients developed distant metastasis without evidence of a local regrowth. The recent 
report of Habr-Gama et al12 on watch-and-wait in 90 patients with a median follow-up of 60 
months showed a local regrowth in 31%, higher than the 14% in the present study. In that 
study the majority was easily amenable to salvage treatment but regrettably four patients 
experienced a further unresectable local recurrence that could only be treated palliatively. 
Two of the 28 patients with a local regrowth developed late metastases, after 2 and 4, and 
it cannot be ruled out that the regrowth was the source of the metastases. Smith et al. 
reported a retrospective series of on watch-and-wait in 32 patients with a median follow-up 
of 28 months with six patients developing a local regrowth (19%). All six regrowths could 
be salvaged by standard TME and remained locally controlled. Two of the six patients 
developed late metastatic disease about a year later and again it cannot be ruled out that the 
regrowth was the source of the late metastases 5. In the prospective trail of Appelt et al. with 
a median follow-up of 24 months, 9/40 patients who entered the watch and wait programme 
developed a local regrowth (23%). All regrowths were detected within 2 years of follow-up 
and underwent salvage surgery. One patient with a regrowth developed distant metastases 
before the local regrowth6. 
The series of Habr-Gama et al.12 illustrates that a watch-and-wait policy carries a small but 
real oncological risk. That this risk seems lower in the present series may be due to chance, 
a shorter follow-up, or can be related to a more strict selection and follow-up program that 
includes state-of-the-art MRI techniques. Only an estimated 17% of the patients treated 
primarily in our centre with chemoradiation were considered cCR, compared to 49% in the 
Habr-Gama series. This suggests inclusion of  larger tumours in our series and possibly also a 
more strict selection in our series. In the first phase of the present study4 we adhered strictly to 
the predefined selection criteria of a completely normalized rectum on DRE, endoscopy and 
MRI. There was only one local regrowth in 21 patients, but one third of complete responders 
were missed and underwent TME. Following this observation it was decided to include 
TEM or a second assessment after 3 months for patients now considered as ‘near complete 
responders’ (Table 1). Although patients that were included at a second assessment after 3 
months were more likely to develop a local regrowth (3yr LR 23% vs 12%) we did not observe 
a compromised outcome with regard to DMFS and OS. In the absence of randomized data 
and very large series it is difficult to calculate an exact oncological risk but based on our 
study and the two series described above we estimate the excess oncological risk of dying 
with a watch-and-wait policy in the order of 2-3% at most. In the shared decision process 
with the patient this needs to be carefully balanced against the operative risk and loss of 
function of major rectal surgery. We experienced that patients are often willing to take this 
small potential risk in order to avoid major surgery, potentially poor functional outcome, 
or a colostomy. Despite the limitations of decision-analytic modelling it is reassuring that a 
recent study showed a calculated operative risk in elderly and comorbid patients that was 
higher than the oncological risk, and in younger patients the risk was equal13. 
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An alternative to repeated assessment in patients with a ‘near complete response’ is a 
local excision, preferably TEM, providing histological proof of a ypT0. The risk of residual 
lymph node metastasis in ypT0 is 5%, as shown in a meta-analysis1. In the current study a 
ypT1-2 tumour that was completely resected by TEM and without evidence of lymph node 
metastases on MRI was considered a candidate for organ-preservation. However, three of five 
patients with ypT2 residual tumour developed a local regrowth, conforming earlier reports 
of high recurrence rates for ypT2, and we now strongly recommend immediate completion 
surgery 14-16. There are some disadvantages of a TEM. We noted a more difficult follow-up due 
to fibrotic changes, and salvage TME can also be more difficult14, 17. Additionally in our series 
three out of seven patients had major incontinence after TEM at the functional evaluation, 
compared to only one of 20 W&W patients. It is unclear if this is related to the higher risk of 
post-operative complications as compared to TEM without CRT9, 14, 18-20. Although it is likely 
that TEM can prevent a number of local regrowths, we feel that its role in organ-preservation 
of rectal cancer is not yet clearly defined. 
There are some limitations to this study. First, a median follow-up of 38 months is generally 
considered short for good estimates for DMSF and OS. Since most regrowths in both our 
series and other series have occurred within the first 18-24 months and 52% patients in our 
series had a follow-up of >3 years, we believe that the results will not change much with a 
longer follow up. Second, the number of patients is relatively small for analyses of differences 
between subgroups. 
Future perspectives
In the present study, the majority of patients received chemoradiation with the goal to 
improve local control after TME surgery for more advanced and distal tumours, not with a 
deliberate goal to preserve the rectum. Patients were offered a watch-and-wait policy only 
when they appeared to have a cCR at restaging. From the patients diagnosed and treated 
in our own catchment area the rate of cCR in these tumours is estimated at 17%. Smaller 
tumours have a higher chance for a complete response, and a number of trials on (chemo)
radiation with the explicit goal of rectal preservation in relatively small tumours have shown 
that this can be achieved in over 50% of patients18, 21. The downside of this approach is that 
the patients who still need major surgery may end up with a worse function than if they 
would have had TME surgery without neoadjuvant therapy. Better prediction methods for 
response to radiotherapy at time of initial diagnosis would better allow a treatment choice 
that minimizes toxicity of futile neoadjuvant radiotherapy.
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Conclusion
Organ-preserving treatment appears to be an oncological safe option for selected rectal 
cancer patients with a clinical complete response after neoadjuvant chemoradiation. When a 
near complete response is observed, a reassessment after 3 months or a TEM are alternative 
options to radical surgery, enabling organ-preservation in more patients. 
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Abstract
Purpose 
To review available literature on tumor size/volume measurements on MRI for response 
assessment after chemoradiotherapy, and validate these cut-offs in an independent 
multicenter patient cohort.
Methods
The study included two parts: 
[1] Review of literature; papers were included that assessed the accuracy of tumor size/
volume measurements on MRI for tumor response assessment. Size/volume cut-offs were 
extracted.
[2] Multicenter validation; Extracted cut-offs from literature were tested in a multicenter 
cohort (n=146). Accuracies were calculated and compared to reported results from literature.
Results
The review included fourteen papers, in which 3 different measurement methods were 
assessed: [1] tumor length, [2] 3-dimensonial tumor size, and [3] whole volume. Study 
outcomes consisted of [1] complete response (ypT0) versus residual tumor, [2] tumor 
regression grade (TRG) 1-2 versus 3-5, and [3] T-downstaging (ypT<cT). 
In the multicenter cohort, best results were obtained for the validation of the whole-volume 
measurements, in particular for the outcome ypT0 (accuracy 44-80%), with the optimal cut-
offs being 1.6 cm3 (post-CRT) and a volume-reduction of Δ80-86.6%. Accuracies for whole-
volume measurements to assess TRG1-2 were 52-61%, and for T-downstaging 51-57%. 
Overall accuracies for tumor length ranged between 48-53% and for 3D-size measurement 
between 52-56%. 
Conclusions
MR-volumetry using whole tumor volume measurements can be helpful in rectal cancer 
response assessment with selected cut-off values. Measurements of tumor length or three-
dimensional tumor size are not helpful. MRI volumetry is mainly accurate to assess a complete 
tumor response (ypT0) after CRT (accuracies up to 80%). 
MRI voluMetRy foR Response assessMent
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Introduction 
Since the introduction of standardized total mesorectal excision (TME) and preoperative 
chemoradiation treatment (CRT), the outcome for rectal cancer patients has considerably 
improved1-3. Preoperative treatment often results in downsizing and downstaging of the 
tumor3, 4, and in 15-20% of the patients even in a complete tumor regression5. In patients 
with a clinically complete or near complete response, organ-preservation (local excision 
or “watch-and-wait”) is now increasingly considered as a potentially good alternative to 
surgical resection6-8. The recommended tools to assess tumor response include digital 
rectal examination, endoscopy and imaging (mainly MRI). MRI, approximately 6-8 weeks 
after completion of chemoradiotherapy9, 10, performs well in assessing tumor regression 
from initially invaded structures and can be beneficial in determining the definitive surgical 
approach11. Although MRI has proven useful to assess changes in tumor volume and 
morphology12, evaluation of minimal residual tumor within post-radiation fibrosis remains 
difficult. As a result, the performance of MRI to assess response after chemoradiotherapy 
remains limited, as was shown in a recent meta-analysis with an overall sensitivity of 
50.4% and specificity of 91.2% for MRI in restaging tumor after CRT10. Various studies have 
investigated the value of measuring changes in the tumor size and/or volume on MRI as a 
predictor of response. Reported results for these measurements vary considerably, with 
overall accuracies ranging between 42%-88%13-27. This could partly be explained by the 
variety in methods for the tumor size/volume measurements (e.g. one-dimensional versus 
3-dimensional versus ‘whole-volume’ volumetry), by the variety in cut-off values, by the 
retrospective nature of the majority of often small-scale studies, and the different study 
endpoints used to define response. Furthermore, prospective validation of retrospectively 
determined cut-offs in an independent and large multicenter patient cohort is lacking. 
Aim of the current study was threefold: [1] to systematically review the available literature on 
the value of tumor size/volume measurements on MRI (using routine T2-weighted sequences) 
for tumor response prediction and assessment in patients with rectal cancer undergoing 
preoperative CRT, [2] to prospectively validate the cut-off values reported in literature in an 
independent multicenter patient cohort, and [3] to evaluate – based on the above two steps 
– whether MRI volumetry is reliable to predict and assess primary tumor response and which 
method and cut-off values would be most accurate.
Materials and Methods
The study consisted of two parts: [1] systematic review of the available literature and [2] 
multicenter validation of the data derived from the literature review.
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1. Literature review
A literature search was performed to identify all papers focusing on assessment of response 
to neoadjuvant treatment in patients with locally advanced rectal cancer by means of 
tumor size or volumetric measurements using routine morphological (T2-weighted) MRI. 
We performed a search of three major databases: Embase, Medline, and Cochrane library 
using (a combination of) the following key words: “rectal cancer”, “rectal adenocarcinoma”, 
“rectal neoplasm”, “response evaluation”, “response assessment”, “response prediction”, 
“radiotherapy”, “neoadjuvant therapy”, chemoradiation”, “chemoradiotherapy”, “tumor 
length”, “tumor volumetry”, “tumor size”, “tumor volume”, “tumor burden”, “tumor regression 
grade”, “tumor regression”, “downstaging”, and “pathological complete response”. Inclusion 
criteria were: (1) tumor size/length or volume was measured on T2-weighted MRI before and/
or after neoadjuvant therapy, (2) the main study outcome was the response to neoadjuvant 
treatment with the standard of reference being pathological complete response, tumor-
downstaging (cT > pT), or favorable tumor regression grade (TRG), (3) cut-off values for tumor 
size/volume were used to determine the diagnostic performance for predicting response, and 
(4) the results were reported in 2x2 contingency tables or these could otherwise be derived 
from the data reported. Two reviewers checked the titles and abstracts of the identified 
studies to determine studies which potentially met the inclusion criteria. Additional studies 
were identified by checking the reference list of the selected studies. Full text copies were 
then studied to decide which articles met the final inclusion criteria. 
2. Validation study
Patients
According to our country’s national law, institutional review board approval is not required for 
this retrospective study and patients consent was waived. For the validation study, 146 locally 
advanced rectal cancer patients were included between 2006-2013 in one of four study centers 
(2 academic referral centers and 2 non-academic centers). None of the patients were previously 
included in any of the previously reported papers included in the review. Inclusion criteria 
consisted of (1) histologically proven rectal cancer, (2) locally advanced rectal cancer (cT3-4 and/
or cN+), (3) long course of neoadjuvant treatment followed by resection, and (4) availability of 
T2-weighted MRI before and after neoadjuvant treatment. The routine neoadjuvant treatment 
protocol consisted of either 50.4 Gy radiation combined with 2x825 mg/m2/day capecitabine or 
45 Gy radiation combined with 225 mg/m2/day 5-fluorouracil (5-FU). Nineteen patients received 
an alternative scheme with additional oxaliplatin and/or bevacizumab. 
Magnetic Resonance Imaging
MRI was performed as part of the routine diagnostic workup for both primary staging and 
restaging after CRT in all centers. The standard interval between completion of CRT and the 
restaging MRI was 4-8 weeks in all centers. The standard MRI protocol included T2-weighted 
Fast Spin Echo (FSE) sequences in 3 orthogonal directions. Slice thickness was 3-3.5 mm. 
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Detailed information on scanning systems, patient preparation, and sequence parameters 
are described in Table 1. 
Table 1. Overview of hardware, sequence parameters and patient preparation.
Image evaluation
MR images were evaluated on an offline workstation using the closed polygon tool in OsiriX 
Medical Imaging Software28 by one reader with 8 years of specific rectal MRI experience (S-
XR). A second reader with 3 years of experience (MHM) re-evaluated the pre- and post-CRT 
images of a random sample of one third (n=48) of the study patients to evaluate interobserver 
reproducibility. The readers were blinded to each other’s results and all clinical and 
histopathological data. Tumor size and volume measurements (including only the tumor in 
the rectal wall, excluding any lymph nodes or extraluminal tumor deposits) were performed 
on the primary staging MRI as well as on the restaging MRI. Measurements were manually 
performed according to 3 different methods (concordant with different methodologies 
described in literature): [1] One-dimensional size measurement of the maximum tumor length 
on sagittal MRI 15, 27, [2] 3-dimensional size measurements (i.e., tumor length (sagittal plane) x 
anterior-posterior (AP) diameter (axial plane) x left-right (LR) diameter (axial plane))26, 27, and 
[3] measurement of the whole tumor volume by manually tracing the tumor boundaries on 
each tumor-containing slice and multiplying these cross-sectional areas by the slice thickness 
(including the slice gap) 13-25. For all 3 methods the percentage of volume/size reduction (VΔ) 
was calculated by (Vpre-Vpost )/Vpre x 100, with Vpre and Vpost representing the volumes/sizes pre- 
and post-CRT, respectively. The different measurement methods are illustrated in Figure 1.
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Figure 1. 
(A) T2-weighted sagittal MRI, the arrow indicates the maximal tumor length (method 1). (B) T2-weighted axial 
MRI, the dashed arrow indicates the left-right (LR) diameter, the filled arrow represents the anterior-posterior 
(AP) diameter (method 2: length x LR x AP). (C) Delineation of the tumor boundaries for method 3 (tumor area 
x slice thickness).
Reference standard
All patients underwent surgical resection. Histopathological examination was performed 
according to the method described by Quirke et al29. The pathological T-stage (ypT) was 
reported for each patient. Tumor regression grade was assessed as part of routine clinical 
care according to the method described by Mandard30 or Dworak31. For study purposes, the 
TRGs measured according to the Dworak classification were converted to the method of 
Mandard, with TRG 1-2 (concordant with Dworak TRG 3-4) being a good response and TRG 
3-5 (concordant with Dworak TRG 0-2) being a poor response32. 
Statistical Analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 20.0, Inc., Chicago, Illinois, USA). For the measurements performed by both 
readers (n=48), interobserver agreement (IOA) was evaluated by calculating the intraclass 
correlation coefficient (ICC) with ICC 0-0.20 indicating poor, 0.21-0.40 fair, 0.41-0.60 moderate, 
0.61-0.80 good and 0.81-1.0 indicating excellent agreement. For all other analyses, the 
measurements of reader 1 were used. Non-parametric Mann-Whitney U test was performed 
to compare the volumes between good/poor responders. Dichotomization between good/
poor responders was performed according to different methods derived from the literature 
review: [1] complete response (ypT0) vs residual tumor, [2] Tumor-downstaging (cT-stage > 
ypT-stage) vs no Tumor-downstaging (cT-stage ≤ ypT-stage), and [3] TRG 1-2 vs TRG3-5, where 
a favorable response (i.e. ypT0, cT>pT, TRG1-2) was consistently defined as the positive 
outcome. Lymph nodes were not taken into account. P-values <0.05 were considered 
statistically significant. Sensitivities, specificities, positive predictive values (PPV), negative 
predictive values (NPV), and overall accuracies including 95% confidence intervals (CI) for 
identifying a good response were calculated using the predefined cut-off values derived from 
the results of the literature review. 
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Results
1. Literature Review
Fourteen papers met the final inclusion criteria.  An overview of these studies is presented in 
Table 2. Two papers focused on the one-dimensional tumor size (method 1)15, 27. Two papers 
evaluated the 3-dimensional tumor size (method 2)26, 27. The majority of the papers (12/14) 
focused on whole tumor volume measurements (method 3). In 2 of the 14 studies, cut-off 
values used were predefined before onset of the study14, 27. In the other 12 studies, cut-off 
values were either retrospectively determined from the study dataset15-19, 21, 22, 26 or it was not 
clearly reported how these were determined13, 20, 23, 25. The results (i.e. accuracy figures) of the 
different studies are given in Table 3.
2. Prospective validation study
Patient and treatment characteristics 
Of the 146 study patients 90 were male and 56 were female (mean age 64.6 years, ±10.8). 
Mean interval between the completion of radiation and restaging MRI was 5.7 weeks (±2.4), 
and mean interval between the completion of radiation and surgery was 10 weeks (±3.8). 
Further patient and treatment details are given in Table 4. 
Interobserver agreement
Interobserver agreement for the one-dimensional measurements (method 1) was good pre-
CRT (ICC 0.78) and post-CRT (ICC 0.66). For the 3-dimensional measurements (method 2) 
agreement was moderate pre-CRT (ICC 0.60) and good post-CRT (ICC 0.61). For the whole-
volume measurements (method 3), agreement was excellent pre-CRT (ICC 0.94) and good 
post-CRT (ICC 0.65). 
Tumor size and volume measurements.
Mean tumor length (method 1) was 5.1 cm (±1.5cm) before therapy and 3.1 cm (±1.1cm) post-
therapy, with a mean decrease (Δ) of -36.6% (±20.2%). Mean volumes according to method 
2 (length x AP x LR) were 57.9 cm3 pre-CRT (±50.6 cm3), 17.0 cm3 post-CRT (±16.1 cm3), and 
VΔ was -65.8% (±23.9%). According to the whole volume measurements (method 3), mean 
volumes were 32.8 cm3 pre-CRT (±25.6 cm3), 10.9 cm3 post-CRT (±11.3 cm3), and VΔ was - 
64.6% (±22.4%). 
Diagnostic performance of predefined cut-off values and comparison with literature
Diagnostic accuracy figures using the cut-off values derived from the literature review are 
provided in Table 3, together with those originally reported in literature. 
 [1] For the one-dimensional size measurements overall accuracy (vs. that originally reported 
in literature) to predict TRG1-2 ranged from 48-53% (vs. 53-68%), sensitivity was 73-93% (vs. 
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75-100%) and specificity 10-36% (vs. 42-46%); the outcomes ypT0 and T-downstaging were 
not reported/studied.  
 [2] For the 3-dimensional size measurements overall accuracy to predict TRG 1-2 was 52-56% 
(vs. 53-60%), sensitivity 36-73% (vs. 35-78%) and specificity 35-73% (vs. 40-73% ); to predict 
ypT0-2 accuracy was 53% (vs. 79%), sensitivity 31% (vs. 100%) and specificity 76% (vs. 75%); 
the outcome ypT0 was not reported/studied. 
 [3] For the whole-volume measurements accuracy to predict a complete response (ypT0) 
was 44-80% (vs. 42-88%), sensitivity 14-100% (vs. 43-100%) and specificity 30-97% (vs. 36-
94%); to predict T-downstaging accuracy was 51-57% (vs. 58-61%), sensitivity 24-52% (vs. 
60-78%) and specificity 64-86% (vs. 52-88%); to predict TRG1-2 accuracy was 52-61% (vs. 49-
82%), sensitivity 36-86% (vs. 35-100%) and specificity 32-83% (vs. 38-88%). 
 When comparing the results for the multicenter validation with those originally reported 
in literature, the prospectively calculated accuracy was >10% lower than originally reported 
in literature in 43% of the tested cut-offs , in 11% overall accuracy was >10% higher than 
originally reported and in the other 46% accuracy was similar (within a 10% range) to the 
originally reported data.
Discussion
Aim of this study was threefold. The first aim was to systematically review all available 
literature investigating the value of tumor size/volume measurements on MRI to predict and 
assess tumor response to CRT in patients with locally advanced rectal cancer. The second 
aim was to prospectively validate different cut-off values derived from the literature review 
in an independent multicenter cohort of rectal cancer patients treated with CRT. The third 
aim was to evaluate – based on the former – whether MRI volumetry is reliable to predict and 
assess the response of the primary tumor to CRT and which method and cut-off values would 
be most accurate.
As expected, the diagnostic performance of retrospectively determined cut-off values 
from literature decreased when tested ‘prospectively’ in an independent new cohort of 
patients. Of the fourteen papers included in the review, cut-off values had been determined 
retrospectively from the study data in the majority (8/14) of studies, while another four 
papers did not report how cut-off values had been defined. Only two papers had defined the 
cut-off values beforehand and already applied the cut-offs prospectively in their study. For 
43% of the cut-offs that were tested, the overall accuracies in our prospective multicenter 
validation cohort were at least 10% lower compared to the results reported in the original 
studies. Similarly, the sensitivity and NPV were at least 10% lower than initially reported in 
44% and 56%, respectively. The specificity and PPV on the other hand were typically similar 
or even >10% better than initially reported. As one would expect, a certain tradeoff between 
sensitivity and specificity was observed depending on the chosen cut-off values. A stricter 
cut-off will result in a higher specificity at the expense of a lower sensitivity and vice versa. 
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Table 4. Patient and treatment characteristics
MRF = mesorectal fascia, 5FU = 5-fluorouracil, LAR = low anterior resection, APR = abdominopereanal resection, 
TEM = transanal endoscopic microsurgery, pCR = pathological complete response, TRG = tumor regression 
grade.
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An important finding of our study is that both one-dimensional (i.e. tumor length) as well 
as 3-dimensional size measurements are insufficiently accurate to assess response. Overall 
accuracy for tumor length measurements in the review ranged between only 53%-68% and 
dropped to 48-53% in our validation cohort. For the three-dimensional size measurements 
(length x AP x LR), the overall accuracies showed a similar trend; moderate accuracies of 
53-79% were reported in literature dropping to 52-56% when prospectively re-tested. In 
contrast, good results were reported for whole-tumor volume with overall accuracies of 
over 80% for both post-treatment and Δ% measurements, which could be reproduced in 
our validation cohort, with accuracies up to 79-80%. Moreover, interobserver agreement 
was considerably better for the whole-volume measurements (e.g. ICC was 0.94 pre-CRT 
versus 0.78 for tumor length and 0.60 for three-dimensional size measurements). The whole-
volume measurements offered the best results for assessment and prediction of complete 
response (ypT0) as the outcome variable, with overall accuracies ranging up to 80%. For 
the other outcome measures – tumor regression grade and T-downstaging – results were 
considerably poorer with accuracies of only 51-60%. Although we have to take into account 
that this discrepancy will also partly be influenced by the fact that a complete response is 
a less prevalent outcome measure than TRG1-2 or T-downstaging, it may also be related 
to intrinsic differences between the outcome measure ypT0 on the one hand, and TRG 
and T-downstaging on the other hand. The relation with the reduction of tumor volume 
is less straightforward in TRG and T-downstaging, than for a complete tumor response. A 
tumor can show a marked volume reduction but still be ypT3 because of a small remnant 
in the mesorectum. Likewise a tumor may shrink considerably but still be a non-responder 
on histological TRG assessment. Additionally, it is known that there is more interobserver 
variation in assessing the histological TRG, compared to assessing a complete regression or 
T-downstaging33. In our study we specifically focused on the response of the primary tumor 
itself and did not take into account the evolution in nodal status, which was beyond the 
scope of this study. 
 For whole-tumor volumetry, the most promising cut-off values to predict ypT0 – based both 
on literature and the validation results – were a volume of 1.6 cm3 post-CRT and a volume 
reduction post-CRT of Δ80-86.6%. The accuracies reported in literature for these cut-offs 
ranged from 72%-88%, prospective validation resulted in comparable overall accuracies 
ranging from 73%-80%, with a corresponding sensitivity of 14-45% and specificity of 80%-
97%. From a clinical point of view, it is particularly important to achieve a high specificity to 
ensure that no residual tumors are missed which would induce a risk for recurrence when 
considering patients for organ-preserving treatments.  The high specificity of 80-97% in our 
validation cohort indicates that most patients with residual tumor will be correctly identified 
and patients have a <3-20% chance of being falsely classified as complete responders. 
However, corresponding sensitivities are relatively poor, indicating that many patients with a 
complete response will be missed and incorrectly diagnosed as having residual tumor. When 
selecting patients for organ-preservation after CRT using MR volumetry to support clinical 
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selection tools would imply a very strict selection, since a substantial number of patients 
with a complete response might not be identified as such. 
In daily radiological practice, a potentially limiting factor of whole-volume tumor volumetry 
is the fact that it is a time consuming procedure. Future work should therefore focus on the 
development of post-processing methods such as auto-segmentation techniques that may 
speed up the process of tumor delineation. In this regard, tumor volumetry using functional 
imaging techniques such as diffusion-weighted MRI (DWI) or FDG-PET have already been 
investigated with good sensitivities up to 70% for assessing a pCR with (semi-)automated 
segmentation34-36. The advantage is that both DWI and FDG-PET have superior strong contrast 
resolution, a prerequisite for automated tumor delineation. 
Our study has some limitations. First, the validation part was performed using routinely 
acquired MRI data from 4 different hospitals. As such, there were variations in MRI hardware, 
scanning protocols and patient preparation. This approach however reflects daily clinical 
practice where protocols are subject to variations between different centers and therefore 
may render our results more generally applicable. Second, there was a subgroup of patients 
(n=19) that underwent an alternative neoadjuvant treatment protocol, potentially affecting 
the treatment response itself. Third, both in literature as well as in our validation cohort, 
there were variable intervals between imaging and surgery, potentially leading to the 
underestimation on imaging of the final histopathological response. Fourth, due to the time 
consuming nature of the study the second reader performed measurements on only a sample 
of patients to test for interobserver differences. Our interobserver agreement was, however, 
fully in line with various previously published results on IOA and we therefore believe that 
our results are representative16, 17, 22, 34. Finally, there were some variations in inclusion criteria 
in the different reports, from which the studied cut-off values were derived. Although overall 
the selection criteria used to establish our current study group corresponded well with those 
applied in literature, these slight variations may have affected the study outcome.
In conclusion, we have shown that MRI volumetry using whole tumor volume measurements 
may be helpful in rectal cancer response assessment when using selected cut-off values. 
Measurements of tumor length or three-dimensional tumor size are not helpful. MRI 
volumetry is mainly accurate to assess a complete tumor response (ypT0) after CRT, but less 
to assess T-downstaging or TRG1-2. Further research should focus on the development of 
automated segmentation techniques which may accelerate the process of tumor delineation 
and facilitate its implementation in clinical practice. 
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Abstract
Objectives
Magnetization Transfer MRI (MT-MRI) utilizes differences in the magnetization interaction of 
free ‘unbound’ water-protons and macromolecular-bound protons. The aim of this study 
was to evaluate if the magnetization transfer ratio (MTR) may be used to identify fibrosis in 
rectal cancer patients treated with chemoradiotherapy.
Materials and Methods
This study was part of a rectal cancer imaging study, approved by the local institutional 
review board. Twenty-six patients, treated with neoadjuvant chemoradiotherapy, underwent 
a standard MRI including T2-weighted sequences and a diffusion-weighted sequence. An 
axially oriented MT-sequence was performed at the center of the (former) tumor location. 
Regions of interest (ROI) were manually drawn on the MT-MRI (with reference to the T2-
weighted and diffusion-weighted images), covering areas of either residual tumor, fibrosis or 
the normal or edematous rectal wall. Results were compared with histopathology. Differences 
in MTR between the four tissue types were analyzed and a receiver operating characteristics 
(ROC) curve was generated to assess the diagnostic potential. 
Results
Thirty-eight ROIs were analyzed on the MT-MRI. The mean MTR of fibrosis was 37.7% ±2.7, 
which was significantly higher than that of residual tumor (29.6% ±4.2, p<0.001), normal 
rectal wall (30.3% ±4.7, p=0.003), or edematous rectal wall (18.2% ±4.0, p<0.001). Use of MTR 
resulted in an area under the ROC curve of 0.96, sensitivity of 88% and specificity of 90% for 
the diagnosis of fibrosis.
Conclusion
MTR can be used to discriminate post-radiation fibrosis from residual tumor and the normal 
rectal wall after chemoradiotherapy. MT-MRI could thus be a promising tool for the unsolved 
dilemma of interpreting post-radiation fibrosis in rectal cancer.
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Introduction
The general treatment for locally advanced rectal cancer is a long course of neo-adjuvant 
chemoradiotherapy (CRT) followed by surgical resection 1. Nowadays, organ-saving 
treatment options (local excision or omission of surgery) for a selected group of good 
responding patients are being considered as good alternatives to standard resection 2-6. 
Critical for a good outcome of organ-saving treatments is the selection of patients: which are 
the patients with residual tumor who still require surgical resection and which are patients 
with a sterilized, fibrotic tumor bed in whom standard resection may be omitted. The role 
of MRI in the workup of rectal cancer patients is well recognized, but its role as a response 
evaluation tool is not yet established. This is partly because morphological information 
from MRI has limited value for the interpretation of post-radiation fibrosis. Fibrosis in the 
irradiated tumor bed is known to contain residual tumor cells in approximately 50% of the 
cases 7. To be on the safe side, radiologists tend to overstage the presence of residual tumor, 
resulting in false positive rates of 75-80% 8,9. Imaging techniques such as diffusion-weighted 
imaging (DWI) have shown promising results in detecting residual tumor. Nevertheless, the 
precise assessment of post-radiation fibrosis remains a challenge 10, possibly explaining the 
relatively poor sensitivity to identify the complete responders with DWI reported by some 
authors (52-64%) 11. An additional tool that could quantify the fibrosis and exclude residual 
tumor could potentially improve treatment response evaluation. 
Magnetization Transfer (MT) imaging is a technique that potentially has the ability to 
quantitatively assess fibrosis. The high collagen content of fibrosis reflects a high density of 
macromolecules. There are two different kind of protons: the free moving bulk water protons 
and the restricted protons that are bound to macromolecules. The latter cannot be directly 
imaged with MRI due to the ultra short T2 relaxation times they exhibit, which is responsible 
for selective signal loss. Magnetization exchange between free and bound protons is taking 
place through dipole-dipole interactions . When an  MT pulse is applied, the bound protons 
are selectively saturated. The magnetization will then be transferred from the free protons 
to the bound protons, resulting in a decrease in MRI signal. The percentage of change of the 
signal intensity before and after the application of an MT pulse is defined as the ‘magnetization 
transfer ratio’ (MTR). In the absence of macromolecules there will be no change in signal and 
the MT ratio will remain low. In tissues with a predominantly macromolecular composition, 
such as fibrosis, the MTR will be high. Hence, the MTR may be used to discriminate between 
fibrotic and non-fibrotic tissues. 
Currently, MT imaging is mainly used in time of flight MR angiography to improve the 
signal contrast between blood and other tissues 12,13, and to improve the detection and 
characterization of white matter lesions in the brain in patients with multiple sclerosis 14-16. 
More recently, MT imaging has been reported to be of value for the evaluation of cartilage in 
osteoarthritis17, the detection of prostate cancer 18, the assessment of breast lesions 19,20, and 
iron deposits in myocardial tissue 21. Furthermore, MT imaging has proven feasible to assess 
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the extent of fibrosis in pancreatic tumors and in Crohn’s bowel strictures 22,23, although the 
evidence so far is only available in preclinical studies.
We hypothesize that in patients with locally advanced rectal cancer the MTR of 
chemoradiotherapy-induced fibrosis on restaging MRI is higher than the MTR of other tissues 
(e.g. tumor, normal rectal wall, and edema). The purpose of this study was to evaluate 
whether it is feasible to differentiate fibrosis from residual tumor in patients with locally 
advanced rectal cancer treated with preoperative chemoradiotherapy using magnetization 
transfer imaging.
Materials and methods
Patients
Thirty-five consecutive patients with locally advanced rectal cancer were considered for 
inclusion in this prospective study between December 2011 and July 2012. The study 
was conducted as part of a rectal cancer imaging study, which was approved by the local 
institutional review board. Inclusion criteria were: 1) biopsy proven rectal cancer, 2) locally 
advanced disease (staged with MRI as cT3-4, involved mesorectal fascia, and/or cN+), and 
3) treated with a long course of neoadjuvant therapy (capecitabine and/or oxaliplatin with 
50.4 Gy, or 5x5 Gy with Rapamycin) followed by surgery. Nine patients did not receive surgery 
and were excluded. This left a total study population of 26 eligible patients. Twenty-two 
patients were male and four were female. The median age was 66.0 years (range 49-80). All 
patients underwent a restaging MRI including MTR approximately 8 weeks after completion 
of neoadjuvant therapy. 
MR Imaging
MR imaging was performed at 1.5 T using a phased array body coil (Intera, Philips Medical 
Systems, Best, the Netherlands).  Patients were placed in feet first supine position and 
received an intravenous injection of 20 mg of butylscopolamine (Buscopan®,Boehringer 
Ingelheim bv, Ingelheim, Germany) to minimize peristaltic movement. Patients did not 
receive any bowel-preparation. The MR protocol consisted of standard T2-weighted (T2W) 
fast spin-echo sequences in three orthogonal planes (TR/TE 8456/130 ms, 90° flip angle, 25 
echotrain length, 6 NSA, 0.78x1.14x3.00 mm voxel size, 30 slices, 6.03 min acquisition time) 
and an axial diffusion weighted sequence (spectral presaturation with inversion recovery, 
b-values 0, 500, and 1000 s/mm2, TR/TE 4971/70 ms, 55 EPI factor, 5 NSA, 1.82x2.31x5.00 mm 
voxel size, 24 slices, 5.33 min acquisition time). One axially oriented slice of the magnetization 
transfer contrast sequence was acquired in the center of the area suspicious for residual 
tumor as visualized on the post-treatment T2W sequence. Parameters of the MT sequence 
were: 2D FFE, TR/TE 32/4.6, 12 ° flip angle, 2 NSA, 1.17x1.47x5.00 mm voxel size, 1 slice, 10 
s acquisition time. The MT-pulse was an on-resonance composite pulse and consisted of 4 
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rectangular pulses (90°-x 90°x 90°x 90°-x) with a duration of 2 ms (0.5 ms for each 90° pulse). All 
axial sequences were angled in identical planes, perpendicular to the tumor axis. 
MR Evaluation
MTR measurements were performed using Weasis Medical Viewer 1.1.2, an open-source 
post-processing tool. MTR maps were generated by applying the following formula on a 
pixel-by-pixel basis: MTR=100x(SIoff-SIon)/SIoff, where SIoff and SIon represent the signal intensity 
with the MT pulse turned off and on, respectively (Figure1). The (T2-weighted) MR images 
obtained before onset of treatment were used as a reference to determine the initial location 
and circumferential growth pattern of the tumor. Two readers in consensus (MHM and  DMJL) 
with respectively one and four years of specific expertise in reading MRI of rectal cancer) 
manually placed regions of interest (ROI). 
Figure 1. 
Axial 2D FFE images obtained before (A) and after (B) application of the magnetization transfer pulse. A 
magnetization transfer ratio (MTR) map was calculated (C). This example shows an area of fibrosis at the ventral 
side, visible as high signal on the MTR map. At the dorsal side an area of normal rectal wall is visualized, showing 
moderate to high signal on the MTR map. The MTR of the area with fibrosis was significantly higher (40.4%) than 
that of the normal rectal wall (30.6%).
ROIs were manually drawn on the MTR-maps covering areas of [1] residual tumor, [2] 
fibrosis, [3] normal rectal wall, or [4] edematous rectal wall, as identified with reference to 
the corresponding T2-weighted and the diffusion-weighted (b1000) images. Areas of residual 
tumor were defined as a wall thickening or mass showing isointense signal on T2W-MRI 
and corresponding high signal on high b-value DWI. Areas of fibrosis were defined as a fully 
hypointense wall thickening on T2W-MRI with no corresponding high signal on DWI. A normal 
rectal wall was defined as a two-layered rectal wall on T2W-MRI consisting of an isointense 
mucosal layer and hypointense muscularis without any visible wall thickening or high signal 
on DWI. An edematous rectal wall was defined as a hyperintense thickened bowel wall on 
T2W-MRI with corresponding low signal on DWI. Depending on the different tissues present 
in the one slice of MTR, a total of 1 to 3 ROIs were included per patient. The mean MTR was 
calculated for each ROI (Figure 2).
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Figure 2. 
Axial T2-weighted image after neo-adjuvant chemoradiotherapy (A), and the corresponding magnetization 
transfer ratio (MTR) map after chemoradiotherapy (B). Regions of interest are determined on the MTR map with 
reference to their morphologic appearance on the T2-weighted images and histopathologic correlation. At the 
dorsal side, histopathology showed extensive fibrosis (arrows) The mean MTR of the fibrosis was 41.9%. On the 
right lateral side residual tumor was present at histopathology (arrow heads), in this ROI the mean MTR was 
25.6%.
Histopathological correlation
For each patients the results of the restaging MRI including the MT sequence were compared 
with histological findings of the resection specimen.The histopathological assessment of the 
surgical resection specimen was performed according to the method of Quirke et al 24. In 
eleven patients an additional staining with Sirius red (specific for fibrosis) was performed to 
allow accurate correlation between the MTR map and histopathology. 
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 18.0, Inc, Chicago, Illinois, USA). One-way ANOVA was used to test differences 
in MTR between the four predefined tissue types (tumour, fibrosis, normal rectal wall and 
edema). A Tukey post-hoc test was used to compare all means of the MTR. A p-value of 
less than 0.05 was considered statistically significant. The diagnostic potential of the MTR 
to diagnose fibrosis was assessed using receiver operating characteristic (ROC) curves 
analysis and the area under the ROC-curve was calculated. The optimal MTR cut-off value 
was determined based on the point nearest to the upper left corner of the ROC curve. 
Corresponding sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) with 95% confidence intervals (CI) were calculated. 
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Results
Patient characteristics
All patients underwent surgical resection: 12 underwent a low anterior resection, 6 
an abdominoperineal resection, 1 a Hartmann’s procedure, 5 transanal endoscopic 
microsurgery, and 2 more extended surgery. At histopathology, 8 patients had an ypT0, 2 
ypT1, 8 ypT2, 7 ypT3, and 1 ypT4 stage. 
MT ratios
A total number of 38 ROIs was analyzed, ranging in size from 15 to 298 mm2 (mean 103.8 
±65.5). The mean MTRs for the four tissue types are displayed in Table 1. The mean MTR 
of fibrosis was 37.7%, which was significantly higher than the mean MTR of residual tumor 
(29.6%, p<0.001), the normal rectal wall (30.2%, p=0.003) and the edematous rectal wall 
(18.2%, p<0.001). There was no significant difference in the mean MTR between residual 
tumor and normal rectal wall (p=0.980). The mean MTR of edematous rectal wall (18.2%) 
was significantly lower than that of both residual tumor and the normal rectal wall (p<0.001). 
Table 1. The mean magnetization transfer ratio for fibrosis, residual tumor, normal rectal 
wall, and edematous rectal wall.
T2W-MRI = T2 weighted MRI, MTR= magnetization transfer ratio, SD= standard deviation.
Histopathological correlation
One of the MR readers was always present during histopathological examination in order to 
ensure accurate correlation between the imaging findings and corresponding histopathology. 
Histopathology (including the Sirius red staining specific for fibrosis) confirmed the presence 
of residual tumor in all patients with ROIs referring to residual tumor, and extensive fibrosis 
without tumor cells in all patients with ROIs referring to fibrosis. In the eleven patients in 
whom additional Sirius red staining was performed on the total rectal wall and surrounding 
mesorectal fat the localization and extension of the fibrotic areas correlated well with the 
MTR maps. Figure 3 shows an example of the correlation between the MTR measurements 
and histopathology including Sirius red staining.
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Figure 3. 
Axial T2-weigthed image (A) and corresponding magnetization transfer ratio (MTR) map (B), b1000 diffusion-
weighted image (C), and whole mount section with Sirius red staining (no magnification) (D) of a patient with a 
cT3N1 rectal tumor that was treated with a long course of neo-adjuvant chemoradiotherapy. Regions of interest 
were determined on the MTR map with reference to the T2-weighted images and diffusion weighted images. 
The mean MTR of residual tumor (arrows) was 23.5% and the mean MTR of fibrosis (arrowheads) was 34.7%. At 
histopathology, these areas corresponded with residual tumor  (arrows) and fibrosis (arrowheads), respectively.
Diagnostic performance
The area under the ROC curve (Figure 4) for differentiating between fibrosis and non-fibrotic 
tissues (e.g. residual tumor and normal or edematous rectal wall) based on the MTR was 0.96 
(95% CI 0.91-1.00). When applying a cut-off MTR value of 34.7%, a sensitivity of 88% (7/8, 95% 
CI 47-99%), specificity of 90% (27/30, 95% CI 72-97%), positive predictive value of 70% (7/10, 
95% CI 35-92%), and negative predictive value of 96% (27/28, 95% CI 80-100%) was obtained.
Figure 4. 
Receiver operating characteristics curve for 
differentiating between fibrosis and non-fibrotic 
tissues using the magnetization transfer ratio (MTR). 
The area under the curve was 0.96 (95% CI 0.91-1.00)
Discussion
The purpose of this study was to evaluate whether it is feasible to differentiate fibrosis from 
residual tumor in patients with locally advanced rectal cancer treated with neo-adjuvant 
chemoradiotherapy using magnetization transfer MR imaging. The MT ratio for the different 
tissue types (residual tumor, fibrosis, normal rectal wall, and edematous rectal wall) was 
MT iMaging: proof of principle
63
Ch
ap
te
r 4
calculated in 26 patients treated with chemoradiotherapy. Our hypothesis was that the MTR 
of CRT-induced fibrosis is higher than that of other tissues. The results of our study support 
this hypothesis and show that MT imaging can differentiate fibrosis from residual tumor and 
the normal or edematous rectal wall with a high AUC of 0.96. 
To our knowledge, this is the first study to assess the potential of MTR to assess bowel fibrosis 
in a human study population. The results are in line with the findings of a previous study 
using an animal model;  Adler et al. investigated whether fibrotic changes in bowel strictures 
in a rat’s model of Crohn’s disease were associated with higher MT ratio’s. They found that the 
MTR increased in areas with fibrosis as found at histology and concluded that MT imaging is 
sensitive to detect bowel fibrosis 22. In addition to bowel fibrosis, Li et al. showed that areas of 
high MTR also correlated with areas of high fibrotic levels at histology in a mouse model with 
pancreatic cancer cell lines 23.  Similarly, MT ratios have also been reported to correlate with 
fibrosis in the breast 25 and in the brain in patients with cirrhotic liver disease 26. Conversely, 
MTR has by different authors been shown to be of limited value for the assessment of fibrosis 
in the liver 27,28. A possible explanation for the lack of increased MTR in liver fibrosis could 
be the diffuse pattern of disease. In the liver, fibrosis develops heterogeneously with the 
formation of fibrotic bands, while in the bowel fibrosis occurs in a focal pattern instead of 
diffuse. This could explain the difficulty of MT imaging to detect fibrosis in the liver.
In patients with rectal cancer, the assessment of fibrosis is a particularly relevant issue, since 
there is increasing evidence showing that organ saving treatment for patients with a true 
complete response (sterilized fibrosis in the tumor bed) is a good alternative to standard 
resection with less morbidity and without compromising outcome 2,3. Crucial in decision 
making is the selection of the patients with a complete response.  Morphological assessment 
of standard T2W-images alone is insufficiently accurate for differentiating between mere 
fibrosis and fibrosis with residual tumor (cells), with reported sensitivities of only 20-42% 
8,9,29. Hence, objective information in addition to subjective morphology may be useful to 
improve the performance in assessing the response to CRT. In this regard, the potential value 
of functional imaging techniques such as FDG-PET 30, dynamic contrast enhanced MRI 31, and 
diffusion-weighted MR imaging (DWI) 11,32,33 have recently been investigated, because these 
techniques can provide additional functional information reflecting the tissue metabolic 
behavior, perfusion characteristics, and cellular tissue structure. The main endpoint of these 
previous studies was the identification of residual tumor and its distinction from a complete 
tumor response. For example, DWI has been shown to be a very sensitive technique to 
detect areas of vital residual tumor after chemoradiotherapy 11,33-35, yet for the qualitative 
(visual) interpretation of DWI in the assessment of a complete tumor response, the reported 
sensitivities remain relatively low, ranging from 52-64% 11. The visual interpretation of DWI 
is generally performed in combination with T2W images for anatomical reference. In this 
setting, extensive fibrosis on T2W images often results in an overestimation of residual tumor 
despite the absence of restricted diffusion (indicating tumor) on DWI. Studies that have 
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applied a quantitative assessment of DWI - i.e. measuring the apparent diffusion coefficient 
(ADC) - have also reported conflicting results. Whereas some authors claim significantly 
different ADC values between patients with residual tumor and patients with a complete 
response 34-36, others found no differences in ADC between the two groups 32,37. A possible 
explanation could be the method of image processing. With the traditional 2 dimensional 
(ROI) data extraction of ADC, the mean ADC over all pixels is generated. This mean ADC 
value does not take regions consisting of fibrosis into account. In particular, in the complete 
response group, results may have been influenced by the contribution of both normal or 
edematous rectal wall tissue components as well as areas of fibrosis within the ROI. This 
may explain why in some studies the measured ADC values were not found to be useful in 
discriminating between the complete response and residual tumor group, in whom similar 
fibrotic areas may be present within the measured ROIs 32,37. In contrast, MT-MRI specifically 
focuses on quantifying the fibrotic tissue compound. The knowledge that sterilized fibrosis 
(complete tumor regression) has a significantly different MTR than all other tissues is even 
more interesting for a precise identification of the true complete responder, who can be 
considered for organ saving treatments.  When further research confirms our findings, MT-
MRI could be complementary to DWI and T2W and information on the response after CRT 
will be more accurate and comprehensive. Our current study was performed at 1.5 Tesla MRI, 
but results should in theory also be reproducible at higher field strengths. Similar results 
have been shown for rectal cancer staging using 1.5T and 3.0T MRI (37,38). Regarding the MT 
sequence, it has been shown that for abdominal MT imaging, MTR values vary only slightly 
between 1.5T and 3.0T MRI38.
Our study was regarded as a ‘proof of principle’ study. As such, there are some limitations to 
the study design. Although the presence of residual tumor and/or fibrosis was histologically 
confirmed for each patient, we did not perform a whole-mount correlation for the MTR 
measurements in each single patient. Secondly, only one slice of the MT sequence was 
currently performed. Now that we have shown the potential value of MT-MRI for assessing 
fibrosis, the next step would be to perform multislice MT-MRI covering the whole tumor 
volume (acquisition time ± 4 minutes) and compare this with whole mount sections of the 
resection specimen. 
In conclusion, this study has shown that magnetization transfer MR imaging may be useful 
in differentiating fibrosis from all other tissues such as residual tumor, normal rectal wall, 
and edematous rectal wall in patients with locally advanced rectal cancer treated with CRT. 
MT-MRI therefore is promising in addressing the yet unsolved dilemma of interpreting post-
radiation fibrosis. The preliminary results are such that further research with a large patient 
cohort is warranted.
MT iMaging: proof of principle
65
Ch
ap
te
r 4
References
1. Glimelius B, Oliveira J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment 
and follow-up. Ann Oncol 2009; 20 Suppl 4: 54-6.
2. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders 
after chemoradiation for rectal cancer. J Clin Oncol 2011; 29(35): 4633-40.
3. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative 
treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. Journal 
of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006; 
10(10): 1319-28; discussion 28-9.
4. Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum 
follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal 
excision after neoadjuvant therapy. Surgical endoscopy 2008; 22(2): 352-8.
5. Borschitz T, Wachtlin D, Mohler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation 
and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008; 15(3): 712-20.
6. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for 
clinical complete responders after chemoradiation. Br J Surg 2012; 99(7): 897-909.
7. Vliegen RF, Beets GL, Lammering G, et al. Mesorectal fascia invasion after neoadjuvant 
chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging 
for prediction. Radiology 2008; 246(2): 454-62.
8. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH. How accurate is magnetic resonance imaging in 
restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis 
Colon Rectum 2005; 48(4): 722-8.
9. Suppiah A, Hunter IA, Cowley J, et al. Magnetic resonance imaging accuracy in assessing tumour 
down-staging following chemoradiation in rectal cancer. Colorectal Dis 2009; 11(3): 249-53.
10. Klauss M, Gaida MM, Lemke A, et al. Fibrosis and pancreatic lesions: counterintuitive behavior of 
the diffusion imaging-derived structural diffusion coefficient d. Invest Radiol 2013; 48(3): 129-33.
11. Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete 
responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann 
Surg Oncol 2011; 18(8): 2224-31.
12. Nezafat R, Han Y, Peters DC, et al. Coronary magnetic resonance vein imaging: imaging contrast, 
sequence, and timing. Magn Reson Med 2007; 58(6): 1196-206.
13. Henkelman RM, Stanisz GJ, Graham SJ. Magnetization transfer in MRI: a review. NMR Biomed 
2001; 14(2): 57-64.
14. Karampekios S, Papanikolaou N, Papadaki E, et al. Quantification of magnetization transfer 
rate and native T1 relaxation time of the brain: correlation with magnetization transfer ratio 
measurements in patients with multiple sclerosis. Neuroradiology 2005; 47(3): 189-96.
15. Papanikolaou N, Papadaki E, Karampekios S, et al. T2 relaxation time analysis in patients with 
multiple sclerosis: correlation with magnetization transfer ratio. Eur Radiol 2004; 14(1): 115-22.
16. Papanikolaou N, Maniatis V, Pappas J, Roussakis A, Efthimiadou R, Andreou J. Biexponential T2 
relaxation time analysis of the brain: correlation with magnetization transfer ratio. Invest Radiol 
2002; 37(7): 363-7.
CHAPTER 4
66
17. Wachsmuth L, Juretschke HP, Raiss RX. Can magnetization transfer magnetic resonance imaging 
follow proteoglycan depletion in articular cartilage? MAGMA 1997; 5(1): 71-8.
18. Kumar V, Jagannathan NR, Kumar R, et al. Evaluation of the role of magnetization transfer 
imaging in prostate: a preliminary study. Magn Reson Imaging 2008; 26(5): 644-9.
19. Bonini RH, Zeotti D, Saraiva LA, et al. Magnetization transfer ratio as a predictor of malignancy in 
breast lesions: preliminary results. Magn Reson Med 2008; 59(5): 1030-4.
20. Leong CS, Daniel BL, Herfkens RJ, et al. Characterization of breast lesion morphology with 
delayed 3DSSMT: an adjunct to dynamic breast MRI. J Magn Reson Imaging 2000; 11(2): 87-96.
21. Papanikolaou N, Ghiatas A, Kattamis A, Ladis C, Kritikos N, Kattamis C. Non-invasive myocardial 
iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio 
measurements. Acta Radiol 2000; 41(4): 348-51.
22. Adler J, Swanson SD, Schmiedlin-Ren P, et al. Magnetization transfer helps detect intestinal 
fibrosis in an animal model of Crohn disease. Radiology 2011; 259(1): 127-35.
23. Li W, Zhang Z, Nicolai J, Yang GY, Omary RA, Larson AC. Magnetization transfer MRI in pancreatic 
cancer xenograft models. Magn Reson Med 2012; 68(4): 1291-7.
24. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to 
inadequate surgical resection. Histopathological study of lateral tumour spread and surgical 
excision. Lancet 1986; 2(8514): 996-9.
25. Matsushima S, Sasaki F, Kinosada Y, et al. Saturation transfer ratio imaging in invasive ductal 
carcinomas of the breast. Magn Reson Imaging 2000; 18(4): 379-85.
26. Miese F, Kircheis G, Wittsack HJ, et al. 1H-MR spectroscopy, magnetization transfer, and 
diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic 
encephalopathy. AJNR Am J Neuroradiol 2006; 27(5): 1019-26.
27. Kim H, Booth CJ, Pinus AB, et al. Induced hepatic fibrosis in rats: hepatic steatosis, macromolecule 
content, perfusion parameters, and their correlations--preliminary MR imaging in rats. Radiology 
2008; 247(3): 696-705.
28. Rosenkrantz AB, Storey P, Gilet AG, et al. Magnetization transfer contrast-prepared MR imaging of 
the liver: inability to distinguish healthy from cirrhotic liver. Radiology 2012; 262(1): 136-43.
29. Dresen RC, Beets GL, Rutten HJ, et al. Locally advanced rectal cancer: MR imaging for restaging 
after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to 
predict tumor confined to the rectal wall? Radiology 2009; 252(1): 71-80.
30. Capirci C, Rubello D, Chierichetti F, et al. Restaging after neoadjuvant chemoradiotherapy for 
rectal adenocarcinoma: role of F18-FDG PET. Biomedicine & pharmacotherapy = Biomedecine & 
pharmacotherapie 2004; 58(8): 451-7.
31. Gollub MJ, Gultekin DH, Akin O, et al. Dynamic contrast enhanced-MRI for the detection of 
pathological complete response to neoadjuvant chemotherapy for locally advanced rectal 
cancer. Eur Radiol 2011; 22(4): 821-31.
32. Curvo-Semedo L, Lambregts DM, Maas M, et al. Rectal cancer: assessment of complete response 
to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry 
versus diffusion-weighted MR imaging. Radiology 2011; 260(3): 734-43.
33. Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted 
MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. 
Radiology 2009; 253(1): 116-25.
MT iMaging: proof of principle
67
Ch
ap
te
r 4
34. Song I, Kim SH, Lee SJ, Choi JY, Kim MJ, Rhim H. Value of diffusion-weighted imaging in the 
detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally 
advanced rectal cancer: comparison with T2 weighted and PET/CT imaging. Br J Radiol 2011; 
85(1013): 577-86.
35. Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and diffusion-weighted 
magnetic resonance imaging for response prediction before, during and after preoperative 
chemoradiotherapy for rectal cancer. Acta Oncol 2010; 49(7): 956-63.
36. Kim SH, Lee JY, Lee JM, Han JK, Choi BI. Apparent diffusion coefficient for evaluating tumour 
response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol 
2010; 21(5): 987-95.
37. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative 
chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for 
early detection of tumor histopathologic downstaging. Radiology 2010; 254(1): 170-8.
38. Martirosian P, Boss A, Deimling M, et al. Systematic variation of off-resonance prepulses for 
clinical magnetization transfer contrast imaging at 0.2, 1.5, and 3.0 tesla. Invest Radiol 2008; 43(1): 
16-26.
68
69
CHAPTER 5
Magnetization Transfer Imaging to assess tumor response 
after chemo-radiotherapy in rectal cancer 
Authors:
M.H. Martens, 
D.M.J. Lambregts, 
N. Papanikolaou, 
S. Alefantinou, 
M. Maas, 
G.C. Manikis, 
K. Marias, 
R.G. Riedl, 
G.L. Beets, 
R.G.H. Beets-Tan
European Radiology, 2015 Jun 12. [Epub ahead of print]
CHAPTER 5
70
Abstract
Purpose
Single-slice magnetization transfer (MT) imaging has shown promising results to evaluate 
post-radiation fibrosis. Aim of study was to evaluate the value of multislice MT imaging to 
assess tumor response after chemoradiotherapy by comparing magnetization transfer ratios 
(MTR) with histopathological tumor regression grade (TRG).
Materials and Methods
30 patients with locally advanced rectal cancer (cT3-4 and/or cN2) underwent restaging MRI 
routinely performed 8 weeks post-chemoradiotherapy, including  multislice MT-sequence, 
covering entire tumor bed. Two independent readers delineated regions of interest on MTR 
maps, covering all potential remaining tumor and fibrotic areas. Mean MTR and histogram 
parameters (minimum, maximum, median, standard deviation, skewness, kurtosis, and 
5-30-70-95th percentiles) were calculated. Reference standard was histological TRG1-2 (good 
response) and TRG3-5 (poor response).
Results 
24/30 patients were male; mean age was 67.7±10.8 years. Mean MTR rendered AUCs of 0.65 
(reader1) and 0.87 (reader2) to differentiate between TRG1-2 versus TRG3-5. Best results were 
obtained for 95th percentile (AUC 0.75- 0.88). Interobserver agreement was moderate (ICC 
0.50) for mean MTR and good (ICC 0.80) for 95th percentile. 
Conclusion
MT imaging is a promising tool to assess tumor response post-chemoradiotherapy in rectal 
cancer. Particularly 95th percentile results in AUCs up to 0.88 to discriminate a good tumor 
response. 
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Introduction
Assessment of response after chemoradiotherapy (CRT) in patients with rectal cancer has 
become increasingly relevant. Until recently, chemoradiotherapy followed by surgical 
resection of the tumor was the standard, irrespective of the response to treatment1. However 
organ-preserving treatments in carefully selected patients who show a clinically complete or 
near-complete response are now considered potential alternatives to resection, albeit still 
controversial. Alternative options include a local excision for a small tumor remnant2 and a 
non-operative management (“wait-and-see” policy) in case of a complete tumor response3-5. 
Critical in these organ-preserving treatments is the availability of tools to accurately select 
the suitable patients. In reported studies so far this has mainly been done by clinical 
examination and endoscopy6. A restaging MRI 8 weeks after chemoradiotherapy has become 
standard in many centers because MRI has proven valuable in assessing tumor downsizing, 
identifying tumor regression from initially invaded structures and thereby altering the 
surgical approach7. However, one of the main challenges of MRI remains the interpretation 
of post-radiation fibrosis8. With morphological MRI it is very difficult to discriminate between 
fibrosis with and without tumor remnants9, explaining the poor sensitivity of 19% reported 
for MRI in a recent meta-analysis for discriminating complete response (pCR) from residual 
tumor10. Quantifying signal intensities on T2-weighted MRI has been suggested to be helpful: 
signal intensity decreases more after chemoradiation in complete responders with a more 
homogeneous signal distribution compared to patients with residual tumor. So far this 
approach has only been addressed by a single report11. Functional imaging techniques such 
as diffusion-weighted imaging and dynamic contrast-enhanced MRI have shown promising 
results in detecting residual tumor after CRT in different reports12-14, but these techniques do 
not specifically target fibrosis. 
In recent reports it was shown that ‘Magnetization Transfer’ (MT) imaging may also be a 
helpful tool to assess bowel fibrosis15-17. MT-imaging is a technique that utilizes differences 
in the magnetization interaction of free, ‘unbound’ water-protons and macromolecular-
bound protons. After applying an MT pulse, there will be a transfer of magnetization from free 
water-protons towards macromolecular-bound water protons. This transfer can only occur 
when macromolecular-bound water protons are present within a given tissue. In tissues 
that are rich in macromolecules (which is typically the case in fibrosis due to the presence of 
collagen), the transfer of magnetization – expressed as the ‘Magnetization Transfer Ratio” or 
MTR – will be high. In a recent proof of principle study of 26 patients with rectal cancer who 
were treated with preoperative CRT, the MTR of histopathologically proven areas of fibrosis 
was significantly higher than that of areas of residual tumor, indicating that there might be 
a potential benefit in adding MT-imaging to a rectal cancer imaging protocol after CRT16. In 
this report, only a single slice of the MT-sequence was acquired, which did not cover (and is 
therefore not representative of) the entire tumor area. As such it is difficult to assess the value 
of MT imaging to evaluate the overall tumor response. Moreover, only mean MTR values were 
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assessed, which provide a rough estimation of the MTR of a given area of interest, but does 
not take into account the heterogeneity of the tumor and fibrosis.
The aim of the current study therefore was to evaluate the potential value of multislice MT-
imaging of the whole tumor volume for assessing tumor response after CRT by comparing 
the magnetization transfer ratios with the tumor regression grade (TRG) as assessed at 
histopathology. A second goal was to assess the added benefit of performing histogram 
analyses as compared to evaluation of only mean MTR values.
Materials and Methods
Patients
This study was performed retrospectively. According to our country’s national law, 
institutional review board approval was not required. All patients were informed that 
their anonymized data could be used for research purposes, to which none of the 
study patients objected. Between November 2012 and June 2014, all consecutive patients 
with locally advanced rectal cancer were considered for inclusion. Inclusion criteria were 
(1) biopsy proven rectal adenocarcinoma, (2) locally advanced disease (cT3/4, and/or N2) 
without distant metastasis, (3) neoadjuvant chemoradiation, (4) availability of a restaging 
MRI including the MT-sequence, (5) resection within 2 months after restaging MRI or in case 
of non-operative treatment and follow-up in patients with a clinical complete response – a 
disease-free follow-up period of > 1 year. 
MR Imaging
MR imaging was performed at 1.5T (Ingenia, Philips Medical Systems, Best, the Netherlands) 
using a phased array body coil. Patients were placed in feet-first supine position and did 
not receive any bowel preparation. To minimize peristaltic movements, patients received an 
intravenous bolus injection of 20 mg of butylscopolamine (Buscopan, Boehringer Ingelheim 
BV, Ingelheim, Germany) . The routine clinical MR protocol included standard T2-weighted 
(T2W) fast spin-echo sequences in 3 planes (sagittal, axial, and coronal). Additionally an 
axial MTR sequence was performed with the following parameters: Multislice fast field echo, 
dynamic (simultaneous acquisition of images with and without MT pulse in one sequence), 
interleaved two-dimensional, TR/TE 50/4.6, 12 ° flip angle, 2 NSA, 1.17x1.47x3.00 mm voxel 
size, 10 slices, 300 x 239 mm field of view, 256 x 162 matrix, receiver bandwidth 147 Hz/
pixel, 5:02 minutes acquisition time. The MT-pulse was an on-resonance composite pulse 
and consisted of 4 rectangular pulses (90°-x 90°x 90°x 90°-x) with a duration of 2 ms (0.5 ms 
for each 90° pulse) and a bandwidth of 2083 Hz. Delay between MT pulse and the following 
excitation was 3.2 ms. The axial T2-weighted and MT sequences were angulated in identical 
planes, perpendicular to the (former) tumor axis as defined on sagittal MRI.
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Image evaluation and calculation of the Magnetization Transfer Ratio (MTR) 
parameters.
Image assessment was performed on the restaging MRI routinely performed 8 weeks 
after completion of CRT. Magnetization Transfer Ratio maps were generated using a freely 
distributed software tool (MANGO; Multi-image Analysis GUI, version 2.6, Research Imaging 
Institute, University of Texas Health Science Center, San Antonio, USA). MTR maps were 
generated using the following formula on a voxel-by-voxel basis: MTR=100x (SIoff – SIon)/
SIoff , where SIoff and SIon represent the signal intensity with the MT pulse turned off and on, 
respectively. Two independent readers with respectively 6 (DMJL) and 3 years (MHM) of 
specific expertise in rectal cancer imaging manually delineated free-hand Regions of Interest 
(ROIs) on the MTR maps on each individual tumor-containing slice. The corresponding T2-
weighted images, as well as the primary staging MRIs were at the readers’ disposal as an 
anatomical reference and to determine the primary tumor location (Figure 1). On every slice, 
the entire area of potential residual tumor was included within the ROI, including any potential 
viable tumor remnants (iso-intense mass or wall thickening), as well as fibrosis (hypo-intense 
wall thickening). The two readers were blinded to each other’s results and histopathology 
outcomes. Histogram analyses were performed using in-house software, developed in the 
programming environment  R language 18. The MTR measurements were imported and 
the following normalized histogram parameters were calculated automatically: minimum, 
maximum, median, standard deviation, skewness (asymmetry of distribution), kurtosis 
(width of peak of distribution), and 5th, 30th, 70th, and 95th percentiles.
Figure 1. 
(A) Axial T2-weigthed MRI at primary staging with ‘T’ indicating the primary tumor. (B) Axial restaging T2-
weighted MRI performed 8 weeks after chemoradiation, (C) corresponding axial MTR map showing the 
delineation of the tumor remnant.
Standard of Reference
Histopathological assessment of the surgical resection specimens served as the primary 
standard of reference. Histopathological assessment was performed according to the 
method as described by Quirke et al. 19. A dedicated GI-pathologist evaluated the tumor 
CHAPTER 5
74
regression grade (TRG) according to the method described by Mandard 20: TRG 1 (complete 
regression) = absence of residual cancer and fibrosis extending to the different layers of the 
bowel wall, TRG 2 = rare residual cancer cells scattered throughout predominantly fibrosis, 
TRG 3 = increase in the number of residual cancer cells but fibrosis still predominates, TRG 4 = 
residual cancer outgrowing fibrosis, and TRG 5 = absence of any regressive changes. Patients 
were then dichotomized into two categories: TRG 1-2 (good response) and TRG 3-5 (poor 
response). 
Statistical analyses
Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS 
20.0, Inc, Chicago, Illinois, USA). Intraclass correlation coefficients (ICC) and Bland Altman 
plots were calculated to determine the interobserver agreement for the MTR measurements 
between the two readers. Receiver Operator Characteristics (ROC) curves were computed 
and corresponding Area’s Under the Curve (AUCs) with 95% confidence intervals were 
calculated to assess the diagnostic performance of the various MTR - histogram parameters 
for discriminating between TRG1-2 and TRG3-5. Predictive value of parameters was assessed 
by logistic regression analyses, parameters were selected for multivariable analyses when p 
was <0.20. For the predicted probabilities for the combined MTR histogram parameters AUCs 
with 95% confidence intervals were calculated. 
Results
Patient and treatment characteristics
Forty-one consecutive patients were considered for inclusion. Eleven patients were excluded 
for the following reasons: delayed surgery after CRT (n=5), mucinous tumor (n=4), or refusal 
of surgery despite clinical residual tumor (n=2). Inclusion process and reasons for exclusion 
are displayed in figure 2.In total 30 patients were included (24 male, 6 female; mean age 67.7 
±10.8 years).  The preoperative treatment consisted of a long course chemoradiation (28x1.8 
Gy + 2x825 mg/m2/d capecitabine) in 28 patients. The remaining two patients received 5x5Gy 
with an interval of 8-10 weeks before surgery. The median interval between the final day of 
radiation and the restaging MRI was 8.9 weeks (range 6.6-24.7). Eighteen patients underwent 
a low anterior resection, 2 an abdominopereanal resection, and 2 transanal endoscopic 
microsurgery. The histological tumor regression grade in these patients was TRG 1 (n=4), 
TRG 2 (n= 5), TRG 3 (n=7), TRG 4 (n=5), and TRG 5 (n=1). Eight patients were followed for > 1 
year according to a wait-and-see policy (median disease free survival of 17.5 months, range 
12-21 months). These patients were all considered TRG1. In total the dichotomized tumor 
regression grade was as follows: n=17 TRG1-2 and n=13 TRG3-5.
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Figure 2. 
CONSORT diagram of patient recruitment and reasons 
for exclusion.
Interobserver agreement
The intraclass correlation coefficients (ICCs) between the two readers for the mean MTR 
as well as the various histogram parameters are given in Table 1. ICC for the mean MTR 
measurements was 0.50 (moderate). The highest ICC’s were obtained for the maximum MTR 
and the 95th percentile with an ICC of 0.80 (good). Figure 3 displays the Bland-Altman plot 
for the mean MTR measurements and for the 95th percentile. The mean bias in mean MTR 
between the two readers was -1.79 and limits of agreement were ± 5.70. For the 95th percentile 
mean bias was -1.22 and limits of agreement were ± 4.67.
Table 1. Intraclass correlation coefficients for the mean MTR and the histogram parameters 
measured after chemoradiation.
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Figure 3. 
Interobserver reproducibility for the mean MTR measurements (A) and 95th percentile MTR (B). Bland-Altman 
plot of the averaged measurement of the two readers (x-axis) plotted against the difference in measurement 
between the two readers (y-axis). The continuous line represents the mean absolute difference (bias) between 
the two readers; the dashed lines represent the 95% confidence intervals of the mean difference (limits of 
agreement).
MTR and histogram parameters
The mean MTR was 59.6 ±3.4 (TRG1-2) versus 58.4 ±3.1 (TRG3-5) for reader 1 (p=0.33) and 62.1 
±1.9 (TRG1-2) versus 59.2 ±1.9 (TRG3-5) for reader 2 (p<0.001). Figure 4 shows the distribution 
in mean MTR values (averaged for the two readers) between the different tumor regression 
grades. The mean 95th percentile was 73.9±4.9 (TRG1-2) versus 70.9±1.8 (TRG3-5) for reader 1 
(p=0.029) and 75.7±3.0 (TRG1-2) versus 71.4±2.4 (TRG3-5) for reader 2 (p<0.001). Table 2 shows 
the results of the receiver operator characteristics curve analyses for discriminating between 
TRG 1-2 and TRG 3-5 for the various histogram parameters as well as for the combined 
assessment of (1) Mean MTR + Skewness (2) Mean MTR + 95th percentile, (3) Skewness + 95th 
percentile, and (4) Mean MTR + Skewness + 95th percentile. The latter combinations were 
derived from the logistic regression analyses. 
The best single parameter to discriminate between TRG 1-2 and TRG 3-5 was the 95th percentile 
for both readers (AUC 0.75 for reader 1 and 0.88 for reader 2). The various combinations 
of Mean MTR, Skewness and the 95th percentile resulted in AUCs of 0.72-0.81 for reader 1 
and 0.87-0.90 for reader 2. This was not a significant improvement compared with the 95th 
percentile as a single parameter (p=0.28-1.00). Sensitivities, specificities, positive predictive 
value, negative predictive value, and overall accuracies of the 95th percentile and the various 
combinations are presented in table 3. Sensitivities and specificities for diagnosing a good 
response ranged between 71-77% and 77-92%, respectively.  
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Figure 4. 
Boxplot showing the distribution of mean MTR 
values between the different TRG subgroups. MTR 
values were averaged between the two readers. 
Table 3: Diagnostic accuracy of MTR parameters
AUC= area under the receiver operating characteristics curve, PPV = positive predicting value, NPV = negative 
predicting value.
Table 2. Results from the Receiver Operator Characteristics Curve analyses for the different 
individual histogram parameters and various parameters combined in differentiating TRG1-2 
from TRG3-5.
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Discussion
The purpose of this study was to evaluate the potential value of whole-tumor MT-imaging to 
assess response after neoadjuvant chemoradiation for rectal cancer. We compared the mean 
MTR as well as various histogram parameters derived from the MTR between patients with 
a good response after CRT (TRG 1-2) and patients with a poor response (TRG 3-5). Results 
showed that MT imaging of the whole tumor volume after CRT could predict a TRG1-2 at 
histology with AUCs up to 0.88 (for the 95th percentile), thereby confirming that MTR is a 
potentially useful help assess fibrosis. 
Interestingly, the best results were obtained for the histogram parameters, in particular 
for the 95th percentile which resulted in high AUCs for both readers (0.75 and 0.88, 
respectively). The 95th percentile represents the value above which the highest 5% of the 
MTR measurements are within a given ROI. In other words, the 95th percentile represents the 
most fibrotic areas within the ROI. It is anticipated that the 95th percentile will be higher in 
patients with a good response (with predominant fibrosis), and lower in patients with a poor 
response. This is indeed supported by the findings of our current study. It also confirms our 
secondary hypothesis that – compared to only analyzing the mean MTR – histogram data 
analysis is advantageous in that it gives us a better insight into the distribution pattern of 
MTR and therefore on the heterogeneity of the tumor area. Moreover, with a good intraclass 
correlation coefficient of 0.80, the 95th percentile appears to be more robust than mean MTR 
values, which showed only a moderate ICC of 0.50. Interobserver reproducibility may thus 
be a limiting factor when assessing MTR. For the mean MTR measurements, the difference 
observed between patients with TRG1-2 and TRG3-5 was in fact smaller than the limits of 
agreement for the difference in MTR measurements between the two readers as derived 
from the Bland-Altman analysis. Although ICC was considerably better for the 95th percentile, 
the mean difference between the two response groups was still smaller than the differences 
in measurements between the two readers. This limits its clinical utility, but could partially 
be explained by the current study methodology, in which ROI placement was performed 
directly on the MTR-maps. The MTR maps (see figure 1) lack anatomical detail, making it 
challenging for radiologists to interpret them. Although corresponding T2-weighted images 
were used for anatomical reference during the delineation process, it may be worthwhile to 
investigate whether it could help to draw the ROIs and copy them from another sequence, 
such as the standard T2-weighted images. A second potential disadvantage of quantitative 
imaging such as MT-imaging is that it can be a somewhat incomprehensible concept 
for clinicians to interpret. A simpler, qualitative approach, such as an MRI-based scoring 
system may be easier for clinicians to understand. The Royal Marsden research group have 
investigated in the mrTRG, an MRI-based scoring system of the tumor regression grade, 
which is constructed similar to the pathological Mandard model 21. In their report, the degree 
of fibrosis determined at pathology was significantly associated with the mrTRG, however 
with moderate interobserver agreement (0.55) 22. This qualitative approach has not been 
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reproduced or validated by other groups so far. For future studies, it would be interesting to 
compare this qualitative approach with MT-imaging for the assessment of fibrosis.
Our current study results are in line with a previous proof of principle study in 26 patients in 
which a single “sample” slice of the MT sequence was obtained after CRT. In this previous study, 
the single slice MTR map was correlated to a corresponding whole-mount histopathology 
section and individual areas of fibrosis, tumor, and the normal rectal wall were compared in 
detail with the underlying histology. This resulted in a significant difference in the mean MTR 
between areas of pathologically proven fibrosis and non-fibrotic areas including residual 
tumor 16. In the current study we did not perform such a detailed whole-mount correlation 
with histopathology but evaluated the overall MTR of the entire tumor area (obtained from 
multislice MT-imaging) to discriminate between good (TRG1-2) and poor response (TRG3-
5) to assess the value of measuring MTR from a more clinical, patient-based perspective. It 
confirmed that whole-tumor MTR can help differentiate between different response groups 
(i.e. patients with varying degrees of fibrosis). Nevertheless MTR measurements mainly 
reflect an estimation of the amount of fibrosis and specific information about the presence 
and extent of residual tumor cells is limited. In this light, it might be interesting to combine 
MT-imaging with other tools that specifically target detection of residual tumor, such as 
diffusion-weighted MR imaging to obtain a more complete understanding of the overall 
tumor response. Diffusion weighted imaging has shown great promise in various studies as 
a sensitive technique for detecting residual tumor within post-radiation fibrosis with AUCs in 
the range of 0.87-0.93 13, 14, 23, 24. As such, the two techniques may be of complementary value in 
assessing the effects of chemoradiotherapy and evaluating the various aspects of treatment 
response. 
The MT ratios found in our study are higher than typically reported in literature. This can 
probably be explained by a combination of factors. First, we used on on-resonance MT 
prepulse, because on-resonance pulse has been suggested to result in are more prominent 
MT effect (resulting in higher MT ratios) compared to use of an off-resonance MT pulse 25, 
26, which are more commonly used in current literature. Other factors that could potentially 
contribute to the relatively high MT ratios in our study are the use of a multislice sequence, 
and the dynamic acquisition of the MT sequence (simultaneous acquisition of images with 
and without MT pulse in one sequence). The fact that factors such as acquisition parameters 
can affect the MTR reveals the need for standardization and calibration of the MT-sequence.
There are some limitations to our study design. First, the studied patient group was relatively 
small. Second, there were some small differences in the neoadjuvant treatment scheme within 
the study group. And finally, not in all patients histopathological confirmation was obtained. 
Eight patients were followed according to a wait-and-see protocol with a recurrence-free 
follow up period of 12-21 months, which was considered a surrogate endpoint for a complete 
response (TRG 1). 
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In conclusion, MT-imaging is a promising tool to assess response after neoadjuvant 
chemoradiation in rectal cancer . In addition to measuring the mean MTR, histogram data 
assessment (in particular the 95th percentile) proved beneficial and resulted in high AUCs 
for differentiating between patients with a good and poor response. A potential limitation 
of MTR is the limited interobserver agreement, which may be improved by adjusting the 
measurement protocol, an item that should be addressed by future studies. 
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Abstract
Background and Purpose
Dynamic contrast-enhanced MRI (DCE-MRI) provides information on perfusion and could 
identify good prognostic tumors. Aim of this study was to evaluate whether DCE-MRI using 
a novel blood pool contrast-agent can accurately predict the response to neoadjuvant 
chemoradiotherapy in locally advanced rectal cancer.
Material and Methods
Thirty patients underwent DCE-MRI before and 7-10 weeks after chemoradiotherapy. 
Regions of interest were drawn on DCE-MRI with T2W-images as reference. DCE-MRI-based 
kinetic parameters (initial slope, initial peak, late slope, and AUC at 60, 90, and 120 seconds) 
determined pre- and post-CRT and their Δ were compared between good (TRG1-2) and poor 
(TRG3-5) responders. Optimal thresholds were determined and sensitivities, specificities, 
positive predictive values (PPV), and negative predictive values (NPV) were calculated.
Results
Pre-therapy, the late slope was able to discriminate between good and poor responders 
(-0.05x10-3 vs 0.62x10-3, p<0.001) with an AUC of 0.90, sensitivity 92%, specificity 82%, PPV 
80%, and NPV 93%. Other pre-CRT parameters showed no significant differences, nor any 
post-CRT parameters or their Δ.
Conclusions
The kinetic parameter ‘late slope’ derived from DCE-MRI could potentially be helpful to 
predict before the onset of neoadjuvant chemoradiotherapy which tumors are likely going 
to respond. This could allow for personalized treatment-options in rectal cancer patients.
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Introduction
After neoadjuvant chemoradiotherapy (CRT) of locally advanced rectal cancer (LARC) 1, 2, a 
complete response is obtained in 8-24% 3-6. There is now a growing awareness of an organ-
preserving approach (local excision of the remaining scar tissue or a non-operative “wait-and-
see” approach) as an alternative curative treatment for these patients 7-9, given the substantial 
risk for morbidity and mortality associated with major resection 10, 11. While currently the 
decision for organ-preservation is made after completion of CRT, knowing upfront which 
patients have a high chance for a good response would be highly advantageous. Moreover, 
it is anticipated that the spectrum of rectal tumors manageable with organ-preservation 
may enlarge and selection criteria may become more liberal. However, it is not justified to 
irradiate all patients knowing that not all tumors will respond and still require TME, resulting 
in worse functional outcome compared with TME without preoperative chemoradiation. 
Apart from this, there may be a subgroup of patients with LARC who may have a reasonably 
good chance for a complete response but require intensification of preoperative treatment 
to increase the chance of obtaining a complete response. Therefore noninvasive tools that 
can predict response before the onset of CRT may allow for a more individualized treatment.
Currently no reliable conventional imaging modalities exist for response prediction, because 
they can only provide morphological information. Dynamic Contrast-Enhanced (DCE) MRI 
is a functional imaging technique, mapping angiogenic microvasculature by measuring the 
inflow and leakage of contrast into the extracellular space. This can be expressed in signal 
enhancement curves from which we can quantify perfusion parameters. These parameters 
reflect the perfusion heterogeneity within the tumor. Therefore DCE-MRI could potentially 
differentiate between good and poor prognostic tumors. Few studies in literature investigated 
DCE-MRI for response prediction to CRT with a conventional low molecular-weight contrast-
agents and showed conflicting results 12-17. We hypothesize that DCE-MRI based on a blood 
pool (e.g. high molecular-weight) contrast-agent is more accurate 18.
The aim of this study was to evaluate whether perfusion parameters derived from DCE-MRI 
using a blood pool contrast-agent measured both before and after neoadjuvant treatment 
can accurately differentiate between good and poor responders in locally advanced rectal 
cancer.
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Material and Methods 
Patients
This study was part of a prospective study on rectal cancer MRI, which was approved by the 
local institutional review board. Between February 2011 and March 2014, 41 consecutive 
patients diagnosed with LARC (cT3-4 and/or cN+) were included. Inclusion criteria consisted 
of (1) biopsy proven rectal cancer (≤15 cm of the anorectal junction), (2) LARC without 
distant metastases, and (3) neoadjuvant CRT. All patients underwent a primary staging MRI 
and a second restaging MRI 7-10 weeks after completion of CRT, both including DCE-MRI. 
Neoadjuvant treatment routinely consisted of 50.4Gy radiation (28x1.8Gy) combined with 
capecitabine (825 mg/m2 twice daily). Eleven of the 41 eligible patients were excluded for 
the following reasons: delayed surgery of > 3 months after restaging MRI (n=7), artifacts on 
DCE-MRI hampering tumor delineation (n=1), and mucinous tumors (n=3) because they are 
known to exhibit different MR enhancing patterns compared to solid tumors.
MR acquisition
All MRI examinations were performed at 1.5T (Intera (Achieva) or Ingenia, Philips Medical 
Systems, Best, the Netherlands) using a phased array body coil. An intravenous bolus 
injection of 20 mg of butylscopolamine (Buscopan®,Boehringer Ingelheim bv, Ingelheim, 
Germany) was administered to reduce peristaltic movement, patients did not receive bowel 
preparation. The standard imaging protocol consisted of T2-weighted sequences in three 
orthogonal planes. DCE-MRI consisted of axial dynamic T1-weighted 3D fast field echo using 
the following parameters: 8 s temporal resolution, TR/TE 7.9/4.6 ms, 30° flip angle, 11 slices, 
5 mm slice thickness, 5 mm interslice distance, 220x220 mm FOV, 256x228 matrix, 6 minutes 
total acquisition time. After 3 series of baseline measurements (24 s), 0.12 ml/kg bodyweight 
of the blood pool contrast-agent gadofosveset (Ablavar®, Lantheus Medical Imaging, North 
Billerica, Massachussets, USA) was administered at a rate of 0.70ml/s into the brachial vein 
followed by a 20mL saline flush using an MR compatible power injector (Spectris Solaris, 
MEDRAD, Warrendale, Pennsylvania, USA). The axial T2-weighted and DCE-MRI sequences 
were angled in identical planes, perpendicular to the tumor axis.
MR analysis
Free-hand regions of interest (ROI) were drawn by a reader, blinded for clinical and 
pathological data, with two years of specific expertise in rectal cancer MRI (MHM), using 
freely distributed medical imaging software (MRIcroN by Chris Rorden, University of South 
Carolina, Columbia, South Carolina, USA). The ROIs were drawn on the DCE-MRI of both 
the primary and post-CRT MRI. The axial T2W images were used as a reference to detect the 
primary tumor and the suspected residual tumor, defined as residual wall thickening with 
either an iso- or hypointense signal intensity at the former tumor location (figure 1). 
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Figure 1. 
Representative T2 weighted images (A & C) and 
corresponding dynamic contrast enhanced 
MRI acquired 56 seconds after administration 
of gadofosveset (B & D) in a patient with locally 
advanced rectal cancer. The upper panel represents 
the MRI of the primary tumor at initial diagnosis (A & 
B) and the lower panel depicts the same level after 
neo-adjuvant chemoradiation (C & D). Regions of 
interest of the primary tumor and the residual tissue 
after chemoradiation are delineated in white.
DCE-MRI analysis was performed on a voxel-by-voxel basis using Matlab (Matlab 2007, 
MathWorks, Natick, Massachussetts, USA). Semiquantitative data analysis was chosen in 
view of the complex pharmacokinetic properties of the protein-binding contrast-agent, which 
affects the conversion of signal enhancement to gadofosveset concentration and applicability 
of the current pharmacokinetic methods. For each voxel, a relative enhancement-time curve 
was obtained according to the equation: Srel(t) = (S(t)-S0)/S0 , where S(t) represents the signal 
intensity at a time (t) and S0 the baseline signal intensity, i.e. the average of the three pre-
contrast scans. Six semiquantitative kinetic parameters were calculated: (1) Initial slope, 
based on the initial 3 upslope data points of the enhancement-time curve. (2) Initial peak, 
represents the magnitude of enhancement at the end of the initial slope. (3) Areas under 
the first 60, 90, and 120 seconds of the enhancement curve (AUC60, AUC90, and AUC120), the 
integrals of the respective data. (4) Late slope, based on the late phase of the enhancement-
time curve, i.e. from the initial peak until the end of acquisition (figure 2). The aforementioned 
parameters are dimensionless since they were calculated from relative enhancement curves. 
Figure 2. 
Schematic representation of the contrast 
enhancement-time curve obtained from the 
dynamic contrast enhanced MRI using blood 
pool contrast-agent gadofosveset. (1) Initial 
slope, (2) initial peak, (3) area under the 
enhancement curve, and (4) late slope. The 
dashed line represents the different types 
of the late enhancement profile (increase 
or decrease). The dotted line represents 
the typical wash out phase in conventional 
gadolinium.
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Histopathology
Histopathological assessment of the resection specimen was performed according to 
the method of Quirke et al 19. Tumor regression grade (TRG) was assessed by a dedicated 
pathologist according to Mandard 20; TRG1: Complete regression, no residual tumor cells, 
TRG2: Predominant fibrosis with isolated tumor cells, TRG3: More residual tumor cells but 
fibrosis still dominant, TRG4: Residual tumor outgrowing fibrosis, TRG5: no regression. 
Therapeutic response was stratified into two groups: Good responders were defined as TRG 
1-2 and poor responders were defined as TRG 3-5 21.
Statistical analyses
All statistical analyses were performed with Statistical Package for the Social Sciences (SPSS 
20.0, Inc, Chicago, Illinois, USA). Normally distributed kinetic parameters were compared 
between good and poor responders using an independent samples T-test. The nonparametric 
Mann-Whitney U test was performed for non-normally distributed data. P-values <0.05 
were considered statistically significant. Multivariate analysis was not performed due to 
the exploratory nature of this study with a limited number of patients. For parameters that 
were significantly different between the response groups, receiver operating characteristic 
(ROC) curves were obtained and the area under the ROC curve (AUC) was calculated. The 
optimal cut-off value was determined as the point nearest to the upper left corner of the ROC-
curve and corresponding sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) including 95% confidence intervals were calculated. 
Results
In total 30 patients were included, the mean age was 66 years (SD±10.1). Table 1 displays 
the patient, treatment, and tumor characteristics. Four patients had a complete response 
on MRI (including diffusion-weighted MRI) and endoscopy and did not undergo surgery but 
were subjected to a stringent follow-up consisting of MRI and endoscopy. These patients 
showed sustained complete response for 12, 13, 13, and 32 months, respectively, and were 
categorized as good responders. All together 13 patients were considered good responders 
(TRG 1-2) and 17 patients as poor responders (TRG 3-5).
The pre-CRT mean of the late slope for good responders (-0.05 x10-3 ±0.34x10
-3) was 
significantly lower compared to that for poor responders (0.62 x10-3 ±0.51x10-3, p<0.001). The 
pre-CRT initial slope, initial peak, AUC60, AUC 90, and AUC 120 were not significantly different 
between good and poor responders (Table 2A). Figure 3 illustrates representative relative 
enhancement-time curves of a good and poor responder. 
The means of the post-CRT initial slope, initial peak, AUC60, AUC90, and AUC120, and late 
slope were not significantly different between good and poor responders (table 2B). 
The percentage of change (Δ) of the parameters was higher for good responders, but not 
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statistically significant. A trend towards significance was seen for the initial slope (35.6% vs 
23.1%, p=0.063), initial peak (31.4% vs 20.0%, p=0.084) , and AUC90 (35.6% vs 23.9%, p=0.079). 
The area under the ROC curve for predicting a good response based on the pre-CRT late slope 
was 0.90 (95% CI 0.78-1.00). The optimal cut-off was determined at 0.258x10-3 and resulted in 
a sensitivity of 92% (12/13; 95% CI 62-100%), specificity of 82% (14/17; 95% CI 56-95%), PPV 
of 80% (12/15; 95% CI 51-95%), and NPV of 93% (14/15; 95% CI 66-100%).
Table 1. Patient-, treatment- and tumor-characteristics
* Tumor regression grade according to Mandard, ^  Consisting of the 4 non-operated patients, n.a. = not applicable
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Table 2: 
Δ
Comparison between good and poor responders with respect to the mean of the kinetic parameters before 
neoadjuvant chemoradiation (A), after neoadjuvant treatment (B), and the percentage of change (Δ) after 
neoadjuvant treatment (C). Data represent the mean ± standard deviation (SD).
* AUC60,  AUC90, and AUC120= Areas under the first 60, 90, and 120 seconds of the enhancement curve
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Figure 3. 
Representative relative enhancement-time curves obtained for the primary tumor before neoadjuvant 
chemoradiation of a good responder (black line) and a poor responder (grey line). The dashed arrows indicate 
the late slope.
Discussion 
The aim of this study was to evaluate whether kinetic parameters derived from DCE-MRI 
using a blood pool contrast-agent and measured before and after CRT, can accurately predict 
which patients will achieve a good (TRG1-2) or poor response (TRG3-5) to CRT in rectal 
cancer. We found that the kinetic parameter ‘late slope’ of the DCE-MRI enhancement curve 
could accurately predict response pre-CRT with an AUC 0.90.  Kinetic parameters measured 
after CRT and their Δ post-CRT did not show significant differences between good and poor 
responders. DCE-MRI before onset of CRT seems promising to identify patients likely to 
respond very well to CRT. 
Currently, no reliable imaging tools exist to accurately predict response to CRT in patients with 
locally advanced rectal cancer. Pretreatment prediction of response using the quantitative 
biomarker “apparent diffusion coefficient” (ADC) from diffusion-MRI, has been the focus of 
research in several studies, showing no clear value and a considerable variation in the mean 
ADC-values between good and poor responders 15, 22-30.  DCE-MRI has only been sparsely 
investigated for response prediction with conventional gadolinium contrast agents and the 
results of published studies are difficult to compare because some used semiquantitative 
and others quantitative analysis and each focused on different parameters. For example 
the groups of Oberholzer 31, George 32, Lim 33, and Intven 34 focused on the quantitative 
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analysis, all found higher pretreatment values for downstaged tumors compared with non-
downstaged. In contrast, Devries et al., who focused on the Perfusion Index (maximum 
slope of concentration-time curve normalized by maximum arterial input function) found 
a significantly lower perfusion index in ypT0-2 tumors compared with ypT3-4 tumors 12, 14, 17. 
Additionally, Kim et al. reported no significant difference in pre-therapy perfusion between 
downstaged and non-downstaged tumors 16. The value of DCE-MRI for response prediction is 
therefore not clear, nor is it clear whether DCE-MRI should be post-processed in a quantitative 
or semiquantitative way.
We found the semiquantitative kinetic parameter ‘late slope’, which we calculated pre-
CRT based on the relative enhancement-time curve, to be highly promising in predicting 
patients who were going to respond well to CRT (AUC 0.90, sensitivity 92%, and specificity 
82%). The pretreatment mean value of this perfusion parameter was significantly lower for 
good compared to poor responders (-0.05x10-3 vs 0.62 x10-3, p<0.001). To our knowledge only 
one paper reported on a quantitative late enhancement parameter (kep) using gadolinium, 
and the results were negative 16.  With gadolinium an obvious wash-out is observed, as a 
result of rapid contrast clearance. However, our large molecular agent is an albumin-bound 
gadofosveset complex, that is formed in the blood stream during the first 30 seconds after 
injection and behaves as a long-circulating blood pool contrast that does not generate a 
typical wash-out phase (figure 2). In normal tissues, the enhancement reaches a steady state, 
whereas in non-irradiated tumors we found either increasing (poor response) or slightly 
decreasing (good response) trend (figure 3). The persistent increasing enhancement has been 
attributed to the steady ongoing extravasation of a large contrast-agent through the leaky 
tumor angiogenic vasculature35. These results support the theory that tumor angiogenic 
activity has a negative impact on therapy outcome 36, 37. We hypothesize that the intrinsic 
tumor aggressiveness may counteract the therapeutic effects of the chemoradiotherapy. The 
advantage of the large molecular gadofosveset is that it requires a lower dose to generate 
the same contrast compared to gadolinium, which is important for reduction of the risk of 
nephrogenic systemic fibrosis 38. 
Second, we used a 3D DCE-MRI sequence, while others used a 2D imaging sequence. It is 
known that 3D acquisition of perfusion MR data at satisfying temporal and spatial resolution 
better represent the tumor heterogeneous state of perfusion than a 2D acquisition. With 
the 3D method, the information is given on the entire tumor while with the 2D method this 
information is only of 1 or 2 slices of the tumor. In other words, a 3D perfusion MRI could 
hypothetically better depict subtle differences in tumor heterogeneity between good 
and poor prognostic tumors, allowing a more accurate prediction of the differences in its 
response to treatment.
The ‘late slope’ parameter calculated from the post-CRT DCE curves in our study did not 
prove efficient for the assessment of response, nor its Δ post-CRT. Although a large increase 
post-CRT was observed for good responders, while it remained relatively constant in poor 
responders, this was not significantly different (table 2C). Radiation treatment is associated 
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with vascular hyperpermeability 39, 40 and we hypothesize that as a consequence of these 
therapeutic effects, the ‘late slope’ lost its diagnostic value.
Predicting tumor response to CRT before the onset of treatment is clinically relevant since 
there is a paradigm shift in treatment towards organ-preservation for patients with clinical 
(near) complete response after CRT. Currently it is not well understood why some patients 
show a dramatic response while others do not. The ability to predict which patients are likely 
to have a (near) complete response to CRT would allow for more rational, cost effective, and 
personalized treatment choices. Patients who will normally undergo major surgery without 
neoadjuvant treatment, but are predicted to show a very good response to neoadjuvant 
chemoradiation, could then be considered for an organ-preservation. Patients with more 
advanced rectal cancer that are likely going to respond well to CRT, could be offered an 
intensified neoadjuvant treatment in order to increase the chance of obtaining a better 
response. The best prediction models will eventually include a variety of predictive factors 
from clinical, imaging, molecular, and other sources41.
There are some limitations to this study. First, this study was performed with a relative small 
sample size. Further research with a larger patient cohort is needed to confirm these results 
and to validate the threshold determined in the current study. Second, the patients in the 
present study were all locally advanced tumors, and it remains to be determined whether 
this predictive effect also applies to smaller tumors. Thirdly, not all patients underwent 
surgery after neoadjuvant treatment, because of suspected clinical complete response 
based on (DWI)MRI and endoscopy and stratification into an organ-preserving treatment. All 
four patients remained free of disease for at least 12 months.
In conclusion, we have shown that the kinetic parameter ‘late slope’ based on DCE-MRI 
with a blood pool contrast-agent could potentially be helpful to predict before the onset 
of treatment which patients with locally advanced rectal cancer are likely going to respond 
to neoadjuvant chemoradiotherapy. This would allow for a more personalized treatment 
stratification.
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Abstract
Objectives
To evaluate the MRI macroscopic and microscopic parameters of mesorectal vasculature in 
rectal cancer patients. 
Methods
13 patients with rectal adenocarcinoma underwent a dynamic contrast-enhanced MRI at 1.5T 
using a blood pool agent at the primary staging. Mesorectal macrovascular features, i.e. the 
number of vascular branches, average diameter and length, were assessed from baseline-
subtracted post-contrast images by two independent readers. Mesorectal microvascular 
function was investigated by means of area under the enhancement-time curve (AUC). 
Histopathology served as reference standard of the tumor response to CRT. 
Results
The average vessel branching in the mesorectum around the tumor and normal rectal wall 
was 8.2±3.8 and 1.7±1.3, respectively (reader 1 p=0.001, reader 2 p=0.002). Similarly, the 
tumor-surrounding mesorectum displayed circa ten-fold elevated AUC (p=0.01). Interestingly, 
patients with primary node involvement had two-fold higher number of macrovascular 
branches compared to those with healthy nodes (reader1: p=0.005 and reader2: p=0.03). A 
similar difference was observed between good and poor responders to CRT, whose tumor-
surrounding mesorectum displayed 10.7±3.4 and 5.6±1.5 vessels, respectively (reader1 
p=0.02, reader 2 p=0.02).
Conclusions
We showed at baseline MRI of rectal tumors a significantly enhanced macrovascular structure 
and microvascular function in rectal tumor-surrounding mesorectum, and the association 
of primary mesorectal macrovascular parameters with node involvement and therapy 
response. 
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Introduction
Blood vasculature is an important constituent of tumor stroma and the proposed medium for 
cancer cell dissemination from the primary tumor to distant metastatic sites 1-4. Notably, the 
formation of reactive vascular stroma also involves the tumor-surrounding host tissues. In 
these areas, the pre-existing vessels enlarge and actively engage in sprouting and branching 
to meet the metabolic demands of adjacent malignancy and create the invasion forefront 
into the neighboring tissue 5-9. 
In contrast to the intensively studied tumor vasculature, the vascular status of tumor-
surrounding host tissue and its diagnostic significance are poorly explored. Previously, the 
enhanced microvascular function in peri-tumoral areas and its potential prognostic value 
was reported in brain cancer patients 6, 10. Moreover, the initial findings in brain and breast 
cancer suggest that the tumor microenvironment influences host vasculature also on the 
macroscopic level, which might be exploited for prognostic and predictive purposes 11, 12. 
The vascular assessment of tumor-surrounding host tissue might therefore provide clinically 
relevant information and complement the current diagnostic strategies in oncology. 
In rectal cancer, the tumor extension into the mesorectal fat and mesorectal node involvement 
are important risk factors, which determine the patient’s prognosis and treatment. Moreover, 
tumor invasion into the surrounding mesorectal vessels has been proposed as a relevant 
prognostic marker 13-15. Previously, the non-invasive detection of mesorectal vasculature 
was based on conventional anatomical T2-weighted images, by exploiting the intrinsic 
negative contrast generated by deoxygenated venous blood 14. However, anatomical 
imaging provides only limited vascular information and, thus, more sophisticated vascular 
imaging methods are needed to advance the knowledge on the mesorectal vascular status 
and its clinical relevance in rectal cancer patients. Among the clinically applicable methods, 
vascular imaging with an albumin-binding blood pool contrast agent, gadofosveset, appears 
to be especially attractive as it enables simultaneous probing of macro- and microvascular 
properties 16, 17.
Our aim was to determine both macro- and microvascular properties of the tumor-
surrounding mesorectum in rectal cancer patients using gadofosveset-enhanced MRI, and 
investigate their relation to the node involvement and therapy response. 
Materials and Methods
Patients 
This prospective study was approved by the local review board and written informed consent 
was obtained from all the patients prior to their inclusion. Thirty primary rectal cancer 
patients treated with neoadjuvant chemoradiation (CRT) in our medical center between 
March 2011 and February 2012 were considered eligible. The following inclusion criteria 
were applied1) histopathologically proven rectal adenocarcinoma, 2) semicircular tumor on 
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anatomical MRI, 3) glomerular filtration rate > 30 ml/min/kg (GFR <30 is a contra-indication for 
gadofosveset), 4) neoadjuvant chemoradiation (50.4Gy in daily fractions of 1.8Gy and 825mg/
m2 oral capecitabine administered twice a day), 5) total mesorectal excision (TME) or in case 
of non-operative treatment and follow-up in patients with a clinical complete response – a 
disease-free follow-up period of > 1 year. In total 17 patients were excluded for the following 
reasons; mucinous tumor (n=2), circular tumor (n=5), ineligible for gadofosveset, i.e. GFR <30 
(n=4), no TME (n=5), or delayed TME (n=1). The final study group consisted of 13 patients 
(1 woman and 12 men). The inclusion of patients with semicircular tumors was motivated 
by the fact that in these patients we could study the vascular abnormalities of mesorectal 
vasculature with respect to the mesorectum around normal rectal wall located within the 
same mesorectal segment (image slice). By this intraslice comparison, we avoided the 
intrinsic vascular differences between the distal, middle and proximal mesorectum. All the 
patients underwent primary staging MRI, followed by a long course of CRT. After a median 
interval of 10.1 weeks (range 8.6-14.9) from the end of CRT, 11 patients underwent TME and 
two patients were followed for > 1 year according to a wait-and-see policy 18, 19. 
To provide histological insights into the primary mesorectal status, we retrospectively 
identified another group of 8 patients with semicircular rectal tumors, who underwent TME 
after only a short-course radiotherapy (5 x 5Gy). The histological material was obtained from 
the Maastricht Pathology Tissue Collection. Collection, storage and use of tissue and patient 
data were performed in agreement with The Code for Proper Secondary Use of Human Tissue 
in the Netherlands. Both patient groups’ characteristics is summarised in Table 1. 
MRI data acquisition
MRI was performed on a 1.5T scanner (Philips Medical Systems, Netherlands) using a 
5-element phased-array coil. The imaging protocol included T2-weighted, diffusion-
weighted and T1-weighted scans, which are routinely used in our medical center for staging 
and restaging of rectal cancer patients. DCE-MRI was performed at primary staging using a 
dynamic 3D T1-weighted gradient-echo scan (TRIVE) on a free-breathing patient, and using 
the following parameters: echo time=4.6ms, repetition time=7.9ms, time resolution=8s (time 
between consecutive DCE-MRI series), total scan time=5min, pixel size= 0.43×0.43×5 mm3, 
field of view=22×22×5.5cm3. After the first three DCE-MRI series, gadofosveset trisodium 
(Ablavar®, Lantheus Medical Imaging, USA), an FDA-approved blood pool contrast agent, 
was administered intravenously at the dose of 0.03 mmol/kg and rate of 0.7ml/s using an 
injection system (Medrad® Spectris Solaris®, MEDRAD, USA). 
MRI data analysis
The clinical assessment of local tumor spread was based on standard T2-weighted images. 
Nodal staging was performed on gadofosveset-enhanced T1-weighted images according to 
previously described criteria 20. A summary of patient clinical characteristics is presented in 
Table 1.
DCE-MRI foR MEsoRECtal vasCulatuRE
103
Ch
ap
te
r 7
Mesorectal microvasculature
First, one reader (MHM) delineated the tumor on T2-weighted images using MRIcron software 
(by Chris Rorden, University of South Carolina, Columbia, South Carolina, USA).. The tumor 
ROIs were subsequently overlaid on T1-weighted images. Only slices in which the tumor was 
visible were included for analysis. For these slices, the subtraction images were created by 
subtracting the baseline contrast (pre-contrast) from the post-contrast T1- weighted images 
obtained at 2 minutes from the start of enhancement, which reflect the steady-state contrast 
conditions 21 (Matlab, Mathworks, USA) (Figure 1).
Table 1. Patient group characteristics
CRT: long chemoradiotherapy with long interval, 5x5 Gy: short radiotherapy; 
TRG: tumor regression grade according to Mandard; ^ non-operated patients, n.a.: not applicable. 
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Figure 1. Definition of the tumor- and normal rectal wall-surrounding mesorectum. 
(A) Representative T2-weighted image with the defined regions of interest in the tumor-surrounding (MT) 
(black line) and normal rectal wall-surrounding mesorectal fat (MN) (white line) used for the analysis of 
macrovasculature. Black arrowheads indicate the normal rectal wall and the white dashed line indicates the 
tumor. (B) Raw post-contrast T1-weighted image with the defined regions of interest in the tumor-surrounding 
(black squares) and normal mesorectal fat (white squares) used for the analysis of microvasculature. (C,D) 
Baseline-subtracted 2 min post-contrast T1-weighted image with the indicated vascular structures (white 
arrowheads) (C) and reader-defined vessel count/length (D). 
Two independent readers (EK and MHM) assessed the macrovascular morphology by 
delineating the vessel branches, measurements of vessel diameter and length, and counting 
the number of vessels on subtraction images using OsiriX software (www.osirix-viewer.com). 
During the analysis, T2-weighted MRI served as anatomical reference. The measurements 
were performed separately for the tumor-surrounding (MT) and normal mesorectum (MN). MT 
was defined as a normal appearing adipose tissue, i.e, hyperintense on fat-unsuppressed 
T2w images, without tumor invasion or desmoplastic reaction, located ipsilateral of the 
tumor and extending from the tumor boundaries until the mesorectal fascia. MN was defined 
as the adipose tissue lying contralaterally to the tumor, neighboring the normal rectal wall 
and extending until the mesorectal fascia (Figure 1). Moreover, to reduce the impact of the 
mesorectal surface area that underwent analysis (MT and MN was 50.2 ± 27.8 cm
2 and 33.6 ± 
16.2 cm2, respectively (p=0.07)), we also calculated the number of vessel branches/cm2.
Mesorectal microvasculature
The microvascular function was assessed by using semiquantitative analysis of the dynamic 
T1w data. First, 3 regions of interest (ROI) were manually selected in the mesorectal fat in 
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the surrounding of the tumor (MT) and normal rectal wall (MN) by one reader (EK) (Figure 
1B) (MRIcron). Post-contrast T1w images were used to select exclusively microvascular tissue 
region and avoid larger mesorectal vessels. Semiquantitative analysis of the enhancement-
time profile was performed using Matlab (Mathworks) on voxel-by-voxel basis. The start of 
enhancement was defined as a first timepoint of DCE-MRI series at which the signal intensity 
(SI) was increased 3× the standard deviation of the noise compared to the baseline SI. The 
baseline was defined as the average of the 7 pre-contrast timepoints. The SI increase was 
normalized to the baseline state, resulting in the relative signal enhancement. Subsequently, 
the area under the first 2min enhancement-time curve (AUC) (arbitrary units (a.u.)) was 
calculated. The mean AUC calculated from all the included voxels of three ROIs was used 
as a semiquantitative indicator of the mesorectal microvascular function. We were not able 
to derive other parameters that we have previously used for characterisation of the tumor 
enhancement profile, such as the initial enhancement peak or initial and late enhancement 
slope 22. This was due to the lack of (at least) three data points in the initial upslope 
enhancement phase and the lack of significant enhancement compared to noise level 
observed both early and late post-contrast, primarily for normal mesorectal data. Therefore, 
for consistency, we selected AUC as the most universal parameter. Samples of the obtained 
average enhancement-time curves are presented in Figure 2. 
Figure 2. 
Average relative signal enhancement-time curves obtained for four different patients for the tumor-surrounding 
(black lines) and normal mesorectum (grey lines).
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Histopathological analysis
The histopathological assessment of TME specimens of patients included in the prospective 
DCE-MRI study was performed by an oncological pathologist (RR) according to the method 
of Quirke et al. 23. Tumor regression grade (TRG) was assessed according to the method 
described by Mandard et al. 24. The patients with TRG 1-2 and ypT0-1N0 were defined as 
good responders and patients with TRG 3-5 and ypT2-3N+ were defined as poor responders 
25. The non-operated patients included in the wait-and-see policy were considered as good 
responders. 
The histological analysis of mesorectal vasculature was performed; 4 µm-thick sections 
of formalin-fixed and paraffin-embedded tumor and normal rectum specimens were cut. 
Before staining, the sections were deparafinized and rehydrated using xylene and decreasing 
concentrations of ethanol, followed by heat-induced antigen retrieval by using Tris/EDTA 
buffer pH=9 (K8004 EnVision™ Flex Target Retrieval Solution High pH 9) (Dako, Heverlee, 
Belgium) for 30 min at 97°C. The sections were stained with either hematoxylin and eosin 
(H&E) (Klinipath, Duiven, Netherlands) or CD31 antibody. In the latter case, the tissues were 
incubated with the monoclonal mouse anti-human CD31 antibody (Clone JC70A) (Dako). 
After 30 min of incubation with the primary antibody, the visualization of CD31 antigen was 
achieved with EnVision FLEX™ + Mouse (LINKER) kit (Dako). Hematoxylin (Dako) was used as 
a nuclear counterstaining. 
The mesorectal macrovasculature was assessed from H&E-stained mesorectal specimens, 
which were scanned using VENTANA iScan HT Scanner (Ventana Medical Systems, Inc., 
Tucson, AZ, USA) and analyzed with Image Viewer v. 3.1.2. software (Ventana Medical 
Systems). The blood vessels were defined by the presence of smooth muscle layer (tunica 
media) surrounded by the connective tissue (tunica adventitia) and frequently residual red 
blood cells in the vessel lumen. For consistency with the MR image-based analysis, only 
vessels with a diameter of approximately 1 mm and higher were included in the analysis. 
Due to a low number of macrovascular structures found in the mesorectal fat specimens, 
i.e, 2-4 vessels per tissue section, only the vascular diameter, measured in the widest vessel 
dimension, was used for statistical analysis. 
The analysis of mesorectal microvasculature was performed on CD31-stained sections by 
using bright field microscopy (Leica DM3000, Leica Microsystems, Wetzlar, Germany) at 200× 
magnification. On average, 10 microscopy images were acquired (Camera Leica DFC 320, Leica 
Microsystems) per tissue section. The fraction of CD31-positive tissue area was determined 
using a custom-made Matlab script (Mathworks). In short, the color threshold was manually 
adjusted to extract the brown-stained tissue area. Subsequently, based on the created image 
mask, the percentage of CD31-positive tissue area was calculated. The average percentage of 
CD31-positive tissue area was calculated from all the analyzed images.
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Statistical analysis
All results are reported as mean±standard deviation (SD). Normality of the distribution of 
all the studied parameters was tested using the Shapiro-Wilk test 26. The comparison of 
tumor-surrounding and normal mesorectum with respect to image- and histology-based 
macro- and microvascular parameters was performed by using a paired t-test. The same test 
was used to determine chemoradiotherapy-induced changes in the image-based vascular 
parameters. The correlation between the image-based macrovascular parameters assessed 
by two independent readers was tested by using intraclass correlation (model: two-way 
mixed, type: absolute agreement). Furthermore, a t-test was used to compare the vascular 
parameters of patients with respect to nodal involvement (cN) and pathological response 
to CRT (TRG and (y)pTN). All statistical analyses were performed using SPSS 16.0 (SPSS Inc., 
Chicago, IL, USA). The difference was considered significant at p<0.05.
Results
Mesorectal macrovascular morphology 
There were significantly more vessel branches per image slice in the tumor-surrounding 
mesorectum (MT) compared to the counterpart around normal rectal wall (MN) reported by 
both readers, i.e., reader 1: 9.0±4.3 versus 1.7±1.2 vessels, p1=0.001; and reader 2: 7.3±3.4 versus 
Figure 3. 
T2-weighted (upper panel) and subtraction images (lower panel) from patients with different orientation of 
rectal tumor. The macroscopic vascular structures are indicated with white arrowheads.
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1.7±1.4 vessels, p2=0.002 (Table 2). This vascular asymmetry was found in all 13 patients, 
independent of the tumor orientation in the rectum (Figure 3). Consistently, we found a 
significantly higher number of vessels per cm2 of MT compared to the normal counterpart MN 
(Table 2). Furthermore, both readers found approximately 0.2mm larger vessel diameter in MT 
(p1=0.025, p2=0.038) (Table 2). The vessel length was similar in both mesorectal compartments 
(Table 2). We found a strong interobserver correlation for the number of vessel branches, i.e., 
the intraclass correlation coefficient (ICC) was 0.94, p<0.0001, and moderate correlation for 
the vessel length (ICC=0.46, p=0.021). However, there was no significant correlation between 
the vascular diameter measurements (ICC=0.34, p=0.092).
Table 2. Comparison between the tumor- and normal rectal wall-surrounding mesorectum 
with respect to macro- and microvascular vascular parameters. 
MT: tumor-surrounding mesorectum, MN: normal rectal wall-surrounding mesorectum, R1: reader 1, R2: Reader 
2, a.u: arbitrary units, * indicates significant difference
Mesorectal microvascular function
In most cases, MT displayed a considerable contrast enhancement, which persisted over time 
(Figure 2). In contrast, in MN, the enhancement was very low and stable over time or absent. 
Consistently, AUC of MT were significantly higher compared to AUC of MN, i.e, 6.4±6.6a.u. 
and 0.6±1.0a.u., respectively (p=0.01) (Table 2), although a large interpatient variability was 
observed.
Mesorectal vasculature and lymph nodes 
The tumor-surrounding mesorectum of patients with malignant nodes (cN1-2) displayed on 
average two-fold higher vascular branching (p1=0.005, p2=0.03) and 0.2mm larger vascular 
diameter (p1=0.008, p2=0.02) compared to that of patients with benign mesorectal nodes 
(cN0) (Table 3). However, the macrovascular length and microvascular function were similar 
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in both patient groups. Furthermore, there were no differences with respect to the vascular 
parameters of MN.
Mesorectal vasculature in good and poor responders to CRT
At the primary staging, thus before therapy, good responders (TRG1-2) had significantly higher 
number of vessel branches in MT compared to poor responders (TRG3-5): reader 1: 11.9±3.5 
versus 5.6±1.5 vessels and reader 2: 9.5±3.5 versus 5.6±1.5 vessels (p1/p2=0.02). A similar 
trend was found when using (y)pTN restaging criteria (p1=0.07, p2=0.09). Other macrovascular 
parameters and microvascular AUC showed no significant association with the response to 
CRT, or, in the case of vascular diameter, only one reader reached the significance level (Table 
3). 
Figure 4. Histological evaluation of mesorectal vasculature at the primary tumor stage. 
(A) In upper panel, the representative images of hematoxylin and eosin-stained sections obtained from the total 
mesorectal excision specimens display the tumor (T) (upper left image) and normal rectal wall (R) (upper right 
image) with the surrounding mesorectal fat. Black arrows depict some of large mesorectal vascular structures. 
In lower panel, the representative microscopy images of the tumor-surrounding (lower left image) and normal 
mesorectum (lower right image) with the CD31-stained microvacular endothelium (brown) and hematoxylin co-
staining (blue). (B,C) The comparison between the tumor-surrounding and normal mesorectum with respect to 
the average macrovascular diameter (B) and microvascular endothelial fraction (C). Bars represent mean ± SD. 
Symbol “*” indicates a significant difference (P<0.05). 
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Histological evaluation of mesorectal vasculature
Histopathology of the 8 patients treated with short course 5x5Gy followed by TME revealed a 
significantly higher vascular diameter in the tumor-surrounding mesorectum MT (1.8±0.3mm) 
compared to the normal counterpart MN (1.3±0.25mm). Figure 4A (upper panel) displays 
representative images of a tumor and normal rectal wall with the surrounding mesorectal fat, 
containing large mesorectal vessels (p=0.027). The microscopical assessment of CD31-stained 
sections (Figure 4A, lower panel) revealed a significantly higher microvascular endothelial 
fraction of 2.7±0.9% in tumor-surrounding mesorectum MT compared to 0.98±0.3% in the 
normal mesorectum MN (p=0.0005) (Figure 4C). 
Discussion
The aim of this study was to investigate macro- and microvascular parameters of the 
mesorectum and their relation to the node involvement and therapy response. The proposed 
vascular MRI method revealed a highly complex macrovascular structure and highly elevated 
microvascular function in the tumor-surrounding mesorectum, i.e., a two- to ten-fold higher 
vessel branching, circa 0.2mm higher vascular diameter and ten-fold higher AUC compared 
to the normal wall surrounding mesorectum. Histological evaluation of the resection 
specimens showed a similar trend in the mesorectal vascular profile, i.e., an approximately 
0.5mm higher macrovascular diameter and 60% higher microvascular endothelial fraction in 
the tumor-surrounding mesorectum. Interestingly, high primary macrovascular parameters 
were significantly associated with nodal involvement and favorable therapy response. 
The tumor-surrounding mesorectal vasculature displayed several abnormal features, 
including a high vascular branching, enlarged vascular radii and enhanced microvascular 
function compared to the mesorectum around normal rectal wall. This vascular profile 
was supported by both imaging (Table 2) and histological parameters (Figure 4). Notably, 
the tumor-associated vascular enhancement was observed independently of the tumor 
orientation in the rectum (Figure 3). Considering the posterior location of superior rectal 
artery 27, one might expect the preference of vascular enhancement in posterior tumors. 
However, our data strongly suggests an angiogenic origin (tumor-induced) of the peritumoral 
vasculature and a limited impact of rectal vascular anatomy. A similarly enhanced vascular 
profile of peri-tumoral tissue areas was previously described in brain and breast cancer 
patients 10, 11, 28. Crucially, however, there are no previous reports on the impact of rectal 
tumor on host tissue macro- and microvascular properties. Thanks to the application of 
gadofosveset, an FDA-approved albumin-binding blood pool contrast agent, we were able 
to generate both the dynamic (functional) and equilibrium phase (steady-state) (structural) 
data during one DCE-MRI scan, which is more time- and cost-effective compared to the 
previously proposed multi-scan approach 29. 
Among the investigated macrovascular parameters, the vascular branching around the 
tumor was found to be the most promising, both considering its significant association with 
the nodal state and therapy response, and excellent interobserver agreement. Although 
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both readers observed differences in the vascular diameter, these were below the spatial 
resolution of DCE-MRI (0.43×0.43mm, in-plane) and led to large interobserver discrepancies. 
The detection of these sub-resolution differences was possible due to the application of 
pseudo-continuous scale ROI tools of OsiriX image software. Therefore, they cannot be 
considered as fully reliable. Nevertheless, our findings on the enhanced vascular branching 
coincide with previous non-contrast magnetic resonance angiography (MRA) studies, which 
showed abnormalities of major cerebral vessels lying outside tumor boundaries 28, and 
their potential prognostic and predictive implications 12, 30. In breast cancer, gadobenate 
dimeglumine-enhanced MRA revealed one-sided increased vascularity associated with 
ipsilateral invasive carcinoma 11. Both our and the aforementioned studies demonstrated 
that the cancer-associated angiogenesis is not limited to microvasculature but also involves 
large vessels, and that blood pool imaging represents a potentially useful strategy in 
cancer diagnostics. Furthermore, our findings suggest that the remodeling of mesorectal 
vasculature occurs in a paracrine manner, presumably mediated by pro-angiogenic factors 
and chemokines released by tumor cells into the surrounding tissue 7, 31. Consequently, the 
mesorectal vascular status might be closely linked to the tumor angiogenic activity and its 
metabolic demands.
Our findings also carry potential clinical implications for patients with rectal cancer. Positive 
extramural venous invasion (EMVI) and nodal malignancy are known poor prognostic 
factors for rectal cancer. Yet assessment of EMVI and nodal stage by imaging is difficult and 
micrometastases remain beyond the image resolution. Considering our initial findings on 
the relation between high mesorectal vascular parameters and nodal involvement (Table 
3), and the co-localization of tumor microlesions with mesorectal vessels, the mesorectal 
macrovasculature parameters should be further investigated as potential prognostic 
markers in rectal cancer. Previously, Sica et al. 10 reported that brain cancer patients with 
hypervascular peritumor tissue have a significantly shorter survival time and an about 3.5-fold 
increase in death risk. Moreover, we observed that highly developed mesorectal vasculature 
predispose to better response to CRT (Table 3). Possibly, the tumor-surrounding mesorectal 
vessels also contribute to the tumor oxygenation and facilitate delivery of cytotoxic agents, 
which increases radiosensitivity. Therefore, the assessment of mesorectal vasculature may 
potentially help to select patients that would benefit from the radiation dose escalation 32. 
Notably, we found no association between microvascular AUC and therapy response, which 
is in line with our previous tumor findings 22. The late slope of enhancement, which we have 
previously shown as a potential predictive tumor marker 22, was unfortunately not easy to 
quantify for the mesorectal fat tissue (Figure 2).
A limitation of our study is a low number of patients and the lack of clinical endpoints to 
determine the diagnostic performance of mesorectal vascular parameters. Furthermore, 
we have no vascular data from control subjects, who would potentially provide better 
representation of the normal mesorectal vasculature. The reader-based analysis of mesorectal 
vascular maps was subjective and time consuming. The clinical application of mesorectal 
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vascular mapping would require the development of (semi)automated and objectivized 
method of vascular assessment. Additionally, the differences in macrovascular diameter 
were smaller than the spatial resolution of DCE-MRI, which resulted in a poor interobserver 
agreement. The method application might be limited by the extent of tumor spread into the 
mesorectum and EMVI, which would mask the presence of mesorectal vasculature. Finally, 
we had no proper histological validation of the vascular imaging data at the primary cancer 
staging, since the mesorectal tissue specimens were available only post-CRT. 
In conclusion, our study demonstrated that the formation of highly vascular stroma in the 
mesorectum of rectal cancer patients precedes the actual tumor invasion. The mesorectal 
vascular enhancement was observed both at the macro- and microscopic level. Moreover, 
MRI-based mesorectal macrovascular parameters showed significant association with the 
primary node involvement and tumor regression after CRT. Further research with a larger 
patients group is warranted to confirm the diagnostic value of the proposed mesorectal 
vascular parameters.
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The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy 
and total mesorectal excision (TME). However there is a trend towards organ-preserving 
options for patients that respond very well to chemoradiotherapy. This approach is still 
considered controversial and is not yet standard practice. It is investigated in several trials 
with close surveillance and registry of patients. Accurate selection of patients is critical to 
minimize over- and undertreatment. Those in favor of organ-preservation, consider absence 
of residual tumor in the resection specimen after TME as overtreatment. On the other hand, 
incomplete response at initial assessment carries the risk for undertreatment and early local 
regrowth (within the first year of follow-up) if organ-preservation was opted for. Possibly long-
term prognosis could be influenced by this over- and undertreatment. The aim of this thesis 
was to evaluate the oncological and functional outcome of organ-preserving treatments. A 
second aim was to investigate modern MRI techniques for improved response assessment 
after therapy, and response prediction before the onset of therapy to allow for optimized 
selection of patients eligible for organ-preservation.
Organ preservation 
The first reports on organ-preservation were from the group of Habr-Gama1, 2. Patients without 
evidence of residual disease at digital rectal examination (DRE) combined with endoscopy 
(and biopsies) were selected for a non-operative ‘watch-and-wait’ strategy (W&W). Their 
most recent paper reported a high clinical complete response (cCR) rate of 49%, but the local 
regrowth rate also increased to 31%3. Similar results were reported in smaller series4-6. Other 
groups reported series of organ-preservation for good responders to neoadjuvant therapy 
with a local excision or transanal endoscopic microsurgery (TEM) of the scar tissue7-9. The 
main benefit of TEM is the histopathological confirmation of the response, a downside is 
the relatively high complication rate10, 11. In the pilot study on W&W from our center by Maas 
et al.5, patient selection was performed with DRE and endoscopy according to the methods 
described by Habr-Gama, but MRI including diffusion-weighted MRI (DWI) and gadofosveset-
MRI was also incorporated. Twenty-one patients with a cCR were included in the watch-and-
wait policy (W&W) and underwent follow-up including DRE, endoscopy, and MRI every 3 
months during the first year, and every 6 months during the next 4 years. With strict selection 
criteria, i.e. (1) substantial downsizing with no residual tumor or residual fibrosis only on MRI 
(with low signal on DWI), (2) no suspicious lymph nodes on MRI (incl. gadofosveset-MRI), 
(3) no residual tumor at endoscopy or a white scar, (4) negative biopsies from the scar, and 
(5) no palpable tumor, only one out of 21 W&W patients developed a local regrowth and 
2-year overall survival was 100%. While these criteria were highly specific for a complete 
response, they were not very sensitive, and a substantial number of patients with a complete 
response were not recognized and still underwent major TME surgery. In chapter 2 the same 
selection criteria for organ-preservation were applied in a larger patient cohort (n=100), but 
now patients with a ‘near complete response’, i.e. not meeting 1 or 2 criteria for a cCR (for 
example: small residual erythematous ulcer on endoscopy, residual tumor on standard MRI, 
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but cCR based on DWI and endoscopy, or equivocal lymph nodes), could still be offered 
organ-preservation. These patients were given the following options: TME, TEM, or a second 
response assessment after 3 months. Patients that had a cCR at this second assessment, 
were offered the watch-and-wait policy at that time. All patients that still did not meet all 
criteria for cCR, e.g. persistent ulcer on endoscopy, or persistent residual tumor on MRI, were 
referred for TME. Of the in total 85 watch-and-wait patients (including the 21 patients from 
the pilot study), 24 were included at the second assessment after 3 months. Although not 
statistically different, 3-year local regrowth free survival was lower in patients included after 
the second assessment compared to those directly included at first assessment (77% vs 88%), 
suggesting that a larger proportion of the ‘near complete responders’ have residual tumor as 
compared to the ‘complete responders’. The main concern is that these patients could have a 
decreased oncological outcome, e.g. higher rates of distant metastasis. In our current cohort 
however, we did not observe a difference in metastasis free survival and overall survival. 
This knowledge allows to further establish a right balance between an acceptable rate of 
false positives (missed residual tumor, i.e. local regrowths) and an acceptable rate of false 
negatives (overlooked complete response, i.e. pCR after resection). Further improvement of 
the response assessment after neoadjuvant therapy could further reduce both false negative 
and positive rates. 
The main benefit of organ-preservation for the patient is avoiding the perioperative morbidity 
and mortality of major surgery, avoiding the need for a (permanent) colostomy, and avoiding 
the long-term anorectal dysfunction that can follow major surgery. This latter aspect has 
not been well studied, and so far only Maas et al. reported less fecal incontinence and better 
bowel function in W&W patients compared to patients with a pCR5. In chapter 2 we observed 
that only one of the 20 W&W patients suffered from major incontinence compared to 3 out of 
7 in the TEM group. Even more, we conducted a retrospective study comparing the long-term 
quality of life (QoL) and the functional outcome of W&W patients to case-matched patients 
that underwent TME and found that W&W patients scored better on several domains12. 
Subsequently, the QoL and functional outcome is now monitored prospectively at short-
term and long-term follow-up. 
Response assessment with imaging 
The main problem with the use of subjective evaluation of morphologic MR features of 
residual disease is the interpretation of post-radiation fibrosis. Fibrotic tissue with and without 
residual small tumor volumes look similar on standard T2-weighted MRI. Areas of apparent 
fibrosis may still contain tumor cells in 50% of the cases13. Therefore, a visual assessment 
on T2W MRI is not accurate to differentiate between residual tumor and complete response, 
with an overall accuracy of only 43%14. 
One of our research questions was whether objective measurements of the size and volume 
of the post-radiation remnant of the tumor bed (i.e. fibrosis and residual tumor) in addition 
to the simple visual interpretation of the images could improve the assessment of response. 
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In chapter 3 we first reviewed all literature on tumor size and volume measurements based 
on standard T2W images. Then we applied the cut-offs derived from this literature in an 
independent multicenter cohort to validate them. Measuring only tumor length or size in 
three dimensions was not accurate to assess tumor response, but measuring the volume 
by manual delineation of the entire tumor resulted in improved results. The best overall 
accuracy was obtained for volume measurements on the post-CRT MRI and the rate of volume 
reduction after CRT. Both cut-offs reached a high specificity to detect a complete response, but 
sensitivities remained low (14-28%), indicating that many patients with a pCR will be incorrectly 
diagnosed as having residual tumor and - using only volume measurements as a criterion - 
will thus be denied the option for organ-preservation. Additionally volume measurements 
on post-CRT MRI are prone to delineation errors. For example, fibrosis that could potentially 
harbor residual tumor could be excluded from the delineated tumor volume or vice versa. 
The question is whether there are imaging biomarkers that can combine morphology with 
underlying tumor biology and thereby improve the response assessment. One of the most 
frequently applied functional MRI technique for response assessment is diffusion-weighted 
imaging (DWI) MRI, which focuses on differences in cellular density between tissues. A visual 
evaluation of residual high signal on DWI after treatment indicates residual tumor, and is easy 
applicable in clinics. The use of DWI for response evaluation has even been recommended in 
an European consensus paper15. However, the sensitivity for detecting a complete response 
remains low (19%)16, although it increases to 65-83% when combined with a quantification 
of the volume of the residual high signal17, 18. Nevertheless, even with DWI difficulties in the 
assessment of post-radiation fibrosis still results in an overestimation of the tumor remnant 
and an additional tool to quantify this fibrosis could be useful.
Magnetization transfer (MT) imaging is such a functional imaging technique that could 
quantitatively assess fibrosis. Fibrosis (e.g. collagen) contains many macromolecules, and 
as MT imaging is based on the presence of macromolecules it therefore has the potential to 
differentiate between fibrosis and residual tumor. In a proof of principle study (chapter 4) we 
showed that the MT ratio was significantly higher in histologically confirmed areas of fibrosis 
compared to areas of residual tumor, normal rectal wall, or edematous rectal wall, confirming 
our hypothesis. The potential of MT imaging was further explored on a patient level in chapter 
5. Results showed that MT imaging can differentiate between patients with a good response 
(TRG1-2) and poor response (TRG3-5) with AUCs up to 0.88. Yet interobserver agreement was 
moderate, which could be partially explained by the study methodology. Regions of interest 
were placed directly on the MTR map with the T2-weigthed MRI as an anatomical reference. 
The MTR maps lack anatomical detail, which makes it challenging to interpret them. Also, 
the measurements were rather time consuming, but this could potentially be solved by the 
development of (semi)automated delineation tools.
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Response prediction rationale 
Our patients series, as well as the series of Sao Paulo, included mostly patients with larger 
and distal tumors, for which CRT is a well-accepted standard neoadjuvant treatment. The 
clinical complete response rates in these larger tumors are generally around 10-20%. Parallel 
to this, a number of studies have explored CRT in smaller tumors, with the explicit goal to 
achieve organ preservation. In this group of patients with generally T1-T2 (or early T3) and 
node negative tumors, neoadjuvant CRT followed by a local excision or TEM resulted in pCR 
rates of 32-38% and organ-preservation was possible for 49-66% of patients (also including 
ypT1)8, 19, 20. The results of a number of similar trials are awaited (Greccar2, TREC). Currently, 
new trials are being conducted to randomize patients between standard treatment (i.e. TME 
without neoadjuvant therapy) and neoadjuvant (chemo)radiation followed by TEM or watch-
and-wait. The downside of this approach is that a sizeable portion of the patients who do 
not have a good response require immediate completion TME. These patients do not benefit 
from the neoadjuvant therapy but suffer from the added morbidity while they could have 
undergone TME without neoadjuvant therapy. A tool that predicts the response before the 
onset of treatment will better enable a differentiation between patients who will respond 
very well to CRT and those who will require TME. Also for patients with more locally advanced 
disease, response prediction could play a role in individualized treatment. For example, 
when a good response is predicted, intensification of treatment with a radiotherapy boost or 
chemotherapy could be considered to further increase the chance of organ-preservation21-24. 
On the other hand, if a poor response is predicted, systemic therapy and surgery are more 
rational treatment modalities than radiotherapy.
Response prediction with imaging
Other than the fact that smaller volumes are associated with a better response, it is currently 
not well understood why some patients show a dramatic response to treatment and others 
do not. Based on a morphological assessment of the primary tumor only, imaging cannot 
accurately predict the tumor response to therapy because most rectal adenocarcinoma, 
except for the mucinous tumors, have similar morphological MR features. MRI can however 
provide more than just morphological information, like in functional MRI techniques, that 
combine morphological features with quantifiable measurements of underlying tumor 
characteristics (biomarkers). Although DWI is a promising technique as a response measure 
after therapy, the role of diffusion in response prediction before the onset of treatment 
has yet to be determined. Some reports have shown promising results for diffusion25-27, 
but others could not confirm this difference between good and poor responding tumors 
measured before the onset of therapy17, 28, 29. A recent pooled-analysis of available literature 
showed an overall accuracy of 68% for response prediction with DWI16. PET-imaging, which 
assesses tumor metabolic activity, is not accurate for response prediction before the start of 
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treatment16, but is reported to be able to predict the tumor response at week 1-2 after the 
onset of treatment with overall accuracies of 81-95%26, 30, 31. 
Tumor perfusion is an important component of tumor pathophysiology and could potentially 
contain information to predict the response to treatment. High perfusion in tumors is 
associated with a higher risk for distant metastasis and poorer survival outcomes32, 33. 
However, the relationship between tumor perfusion and response to neoadjuvant therapy is 
not clear yet. Poor tumor perfusion results in hypoxic areas, which are known to be resistant 
to radiotherapy34. Also, hypoxia causes cells to stop or decrease cell proliferation35, possibly 
reducing the cytotoxic efficacy of chemotherapy, which is more effective against rapidly 
proliferating cells. This would indicate that poorly perfused tumors are associated with a 
poor response due to hypoxia. Tumors with a high perfusion are generally better oxygenated, 
which would imply a good response to radiotherapy. Furthermore, tumor perfusion is a 
prerequisite for the delivery and consequently the effectiveness of chemotherapy, thus a high 
perfusion could be associated with a good response to chemotherapy. On the other hand, 
high tumor perfusion indicates a high angiogenic activity, which is associated with a higher 
tumor aggressiveness.. This would mean that tumors with high perfusion are associated 
with a poor response. Keep in mind that vascularization and perfusion are two different 
definitions and a high vascularization does not automatically translate in high perfusion, 
since angiogenic vessels are leak and disorganized and often result in irregular blood flow 
and an heterogeneous blood distribution within the tissue. 
Tumor perfusion as measured by dynamic contrast-enhanced MRI (DCE-MRI) has been 
investigated for the prediction of tumor response before the onset of therapy. The results 
of different studies are difficult to compare because different quantitative and semi-
quantitative analyses have been reported, and a high tumor perfusion has been reported to 
be associated with both poor36-38 and good39-44 tumor response. In chapter 6 we found that 
tumors characterized by a higher ‘late slope’, which implies a higher vascular permeability, 
were associated with poor response, hence supporting the hypothesis that tumors with 
high angiogenic activity are aggressive and poorly responding tumors. In chapter 7 we 
investigated the macro- and microvasculature in the mesorectum surrounding the tumor. A 
high microvasculature was associated with a poor tumor response, in accordance with our 
previous results on tumor perfusion. Interestingly, enhanced mesorectal macrovasculature 
was associated with a good tumor response, possibly referring to the importance of adequate 
delivery of chemotherapy. 
Considering the current trend towards organ-preservation for early tumors, it would be 
interesting to investigate if DCE-MRI can also predict the response in early tumors and 
possibly select the patients who would benefit from neoadjuvant treatment. Hopefully, this 
diagnostic technique can be combined with the ongoing and future trials for neoadjuvant 
therapy in early tumors. 
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Future perspectives and recommendations
Although organ-preservation in rectal cancer is still controversial, it is gaining interest from 
both clinicians and patients. Even though in this thesis we showed excellent long-term 
outcomes in a cohort study, data on more patients with a longer follow-up are required to 
provide more evidence on the oncological safety of this approach. Recently, a multicenter 
collaboration has started an international database aiming to concentrate data of the main 
organ-preservation initiatives throughout the world. Patient selection is crucial in organ-
preservation and many imaging techniques, both morphologic and functional, have been 
reported as valuable tools to assess tumor response after neoadjuvant chemoradiation. 
However, further large scale multicenter studies should be conducted to identify the 
most valuable imaging modalities that have the potential for implementation for non-
expert radiologists in daily practice. A recent study shows that the combination of clinical 
assessment and MRI (including DWI) results in a better accuracy to detect patients with a 
complete response compared to a single modality approach45. More combinations of 
several parameters, both imaging, clinical (e.g. digital rectal examination, endoscopy), and 
biomarkers should be investigated to result in a model with the highest accuracy of response 
assessment to enable optimal patient selection. Imaging parameters should be standardized 
before implementation on a large scale is possible, especially for quantitative parameters. 
Quantitative imaging assessment requires post-processing that is often time-consuming and 
can be technically challenging. Fully and semi-automated post-processing tools should be 
developed to facilitate implementation in routine practice. 
In addition, imaging modalities for response prediction before the onset of therapy, and 
early during treatment, should be further explored. Prediction of the response before or 
early during treatment, could allow patient-tailored therapy with intensified, reduced, or 
alternative treatments. DCE-MRI seems promising for response prediction, and PET during 
therapy. With the development of PET-MRI, there is a new possibility to combine PET with 
DWI and DCE-MRI.
Based on all the above, organ-preservation for complete responders after neoadjuvant 
treatment appears to be a oncological safe and functionally good option as an alternative 
to the presently still standard indicated TME. Patients with a near complete response at 
initial response assessment could go for TEM or a second assessment 3 months later. These 
patients will however have a higher chance of having residual tumor, with a higher risk of 
a local regrowth during the first year of follow-up. Patient selection remains difficult and 
should be performed with caution, preferable by centers with expertise.
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Cancer is still one of the most leading causes of death is Europe and its incidence is expected 
to increase in the near future. Colorectal cancer is the second most common cause of cancer-
related death in both men and women. Of all colorectal cancers, approximately one third 
comprise rectal cancer, making rectal cancer an important health care problem. Symptoms 
that can occur in rectal cancer are bloody stools, change in size, shape, or frequency of stools, 
not being able to completely empty the bowel, abdominal pain or discomfort, unintended 
weight loss, and fatigue. Patients suspected for colorectal cancer will undergo an endoscopic 
examination of the colon combined with biopsies of any suspect tumoral lesions. When 
histopathological examination of these biopsies show cancer cells, the diagnosis of rectal 
cancer is confirmed. To evaluate the stage of disease, imaging is obtained of the local tumor 
but also of the liver and lungs, which are at risk for distant metastases. For assessment of the 
local extent of the tumor and possible invasion of local lymph nodes, MRI is performed. 
Traditionally, rectal cancer was associated with a poor prognosis, mainly due to the high risk 
of a local recurrence of the tumor after surgery. A local recurrence is often diagnosed in an 
advanced stage when surgical resection is not possible anymore. It is associated with impaired 
quality of life, severe pain, and immobilization. Treatment often involves radiotherapy, 
chemotherapy, and/or extensive surgery (if operable). Fortunately, local recurrence rates 
have decrease significantly due to standardized surgical techniques and the introduction of 
pre-operative (chemo)radiotherapy. However, the benefit of preoperative treatment depends 
on the presence or absence of risk factors associated with a local recurrence. The national 
guidelines for rectal cancer treatment are based on these risk factors.
Patient with a low risk for local recurrence will undergo surgery without preoperative treatment, 
patients with an intermediate risk are treated with a short course of preoperative radiation 
therapy followed by surgical resection, and patients with a high risk are treated with a long 
course of radiation therapy combined with chemotherapy followed by surgery. The main 
aim of the combined chemoradiotherapy is to induce tumor downsizing and downstaging 
to increase the chance of a complete resection of the tumor and lymph nodes and therefore 
reducing the risk of a local recurrence. In approximately 15-20% of the patients treated with 
preoperative chemoradiotherapy, no residual cancer cells are found at histopathological 
examination of the surgical specimen. This means that the cancer has disappeared completely 
as a result of the preoperative chemoradiotherapy. One could wonder whether major surgery 
is still required when the tumor has already disappeared, especially when considering the 
risks of surgery. An alternative strategy could be an organ-preserving treatment, such as a 
local excision of the remaining scar-tissue or even no surgery at all but a stringent follow-up. 
Benefits of this strategy are the omission of major surgery which is associated with morbidity, 
a temporary or permanent colostomy, functional impairment, and a mortality-risk of 4-12%. 
The potential risk or organ-preservation is an undertreatment of wrongly selected patients 
who still have a viable tumor after chemoradiotherapy. Therefore, accurate patient selection 
is of the utmost importance. When patients with a persistent tumor after chemoradiotherapy 
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are wrongly selected for organ-preservation, they are at risk of regrowth of the tumor and 
potentially at a greater risk for distant metastasis. Currently, organ-preserving treatment is 
still controversial in rectal cancer management and different strategies of patient selection 
and follow-up are being practiced. 
Relevance of scientific results in this thesis
The results of this thesis show that organ-preservation is a feasible and oncologically safe 
option for selected patients. Organ-preservation has the potential to improve the quality 
of life of rectal cancer patients. Patients will not have to undergo surgical resection, and 
therefore they will not be exposed to the associated morbidity and mortality. Furthermore, 
the risk of a colostomy is prevented, resulting in an improved quality of life.
The results of this thesis are based on patients with locally advanced rectal cancer who were 
treated with neoadjuvant chemoradiotherapy as part of the national guidelines. However, 
this strategy could also work in earlier stages of rectal cancer, as was shown in several 
trials. Early rectal cancer will respond better to the chemoradiotherapy, therefore organ-
preservation could be become a feasible option for more patients (up to 66% of the patients). 
Recently, the Netherlands introduced a national screening program for colorectal cancer. 
This will result in an increase in rectal cancer patients, especially in the rate of early rectal 
cancers. Both pre- and post-therapy prediction of response could play an important role in 
optimizing individualized treatment and improving quality of life. 
In this thesis novel MRI techniques are described to improve patient selection for organ-
preserving treatment. When these sequences are further developed and optimized, MRI 
vendors can deliver these techniques on their MRI machines as a standard protocol. 
In the current thesis several post-processing techniques have been explored, such as 
histogram analyses and subtraction images. Such tools, but also techniques like a (semi)
automated contouring system, can be further developed and offered as part of post-
processing software. The continued development of both the MRI sequences and post-
processing software will be in close collaboration with the manufacturers and vendors. 
Target population
According to the national guidelines, all patients with a high-risk tumor are treated with 
preoperative chemoradiotherapy followed by a surgical resection. Approximately 15-20% of 
these patients will have a complete response of the tumor and could be considered for an 
organ-preserving treatment. As mentioned before, organ-preservation could also be feasible 
for patients with an early stage of rectal cancer. 
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Innovation and future
The principle of organ-preservation for selected rectal cancer patients has been shown to 
be feasible and oncologically safe, although data on more patients and longer follow-up 
is desirable. Recently, a multicenter collaboration has started an international database in 
which the data of main organ-preservation pioneers is centralized. Furthermore, data on 
functional outcome of organ-preservation is scarce. We have started a prospective study to 
monitor the quality of life and functional outcome of these patients at several time-points 
over a period of 5 years. 
Accurate patient selection for organ-preservation remains crucial. Multicenter studies with 
both imaging and clinical response assessment are required to identify the most valuable 
modalities and in particular to identify the optimal combination of parameters. 
Response prediction before the onset of treatment has been shown to be feasible in a selected 
patient group. Further validation in a larger cohort is necessary. Then the next step would be 
implementation in a clinical trial in which preoperative treatment is adapted according to 
the chance of a complete response, for example by intensification of preoperative treatment.
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Summary
The aims of this thesis were to evaluate the oncological outcome of organ-preservation in 
rectal cancer management, to investigate how to improve patient selection by means of 
modern MRI techniques, and asses the feasibility of a novel MRI technique to predict the 
response before the onset of treatment.
PART I: Organ preservation
In chapter 2, the oncological results of our initially promising pilot results on watch-and-wait 
were investigated in a larger cohort. The second aim was to update the selection and inclusion 
criteria. Patient selection was performed with digital rectal examination, endoscopy, and 
state-of-the-art MRI. Patients with a clinical complete response were included in the watch-
and-wait regimen. Patients with a near clinical complete response were offered 3 options: 
standard surgical resection, TEM, or a second assessment 3 months later. One-hundred 
patients were included in an organ-preservation treatment, either watch-and-wait (n=85), 
or a TEM (n=15). The median follow-up was 38 months. Fifteen patients developed a local 
regrowth, all salvageable and all within 25 months. Five patients had distant metastases and 
four patients died. Three-year local regrowth free survival was 84% and overall survival was 
96%. Functional outcome was good since only 1/22 patients in the watch-and-wait group 
suffered from major incontinence. Therefore, organ-preservation appears oncologically safe 
for selected rectal cancer patients.
PART II: Response assessment after therapy
Chapter 3 reviews the available literature on tumor size and volume measurements based 
on standard T2-weighted MRI for response assessment after chemoradiotherapy. Based on 
the results of this review we prospectively validated the cut-offs from the reviewed studies 
in a multicenter cohort and determined the optimal cut-offs to predict response. In total 14 
papers reported three different measurement methods (length, 3D-size, and whole volume), 
and three different study outcomes (complete tumor response, tumor regression grade 1-2, 
and tumor-downstaging). Tumor length and 3D-size were not helpful to assess the tumor 
response. Whole volume measurements were promising, especially for assessing a complete 
tumor response with an overall accuracy of up to 80%. However, since sensitivities remained 
low (14-21%), its application in daily clinics remains limited.
Chapter 4 explores the potential of the novel MR technique “magnetization transfer” 
(MT) imaging to differentiate between residual tumor and fibrosis after neoadjuvant 
chemoradiotherapy. Regions-of-interest were measured on the MT images and correlated 
with the histopathology. This proof-of-principle showed a significantly higher MT ratio in 
regions of fibrosis (38%) compared to regions of residual tumor (30%, p<0.001). The sensitivity 
and specificity were 88% and 90% for detecting fibrosis with MT. Therefore, MT ratio could be 
a promising tool to differentiate between fibrosis and residual tumor.
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In chapter 5, we evaluated the value of MT imaging to differentiate between patients with a 
good and a poor response after neoadjuvant therapy. The mean MT ratio showed an AUC of 
0.65 and 0.87 for two readers. However, the 95th percentile of the MT ratio rendered an AUC 
of 0.75-0.88 with a good interobserver agreement (ICC 0.80). Magnetization transfer imaging 
seems a promising tool, but it should be further explored in a larger patient cohort.
PART III: Response prediction before therapy
Chapter 6 focuses on the performance of dynamic contrast enhanced (DCE) MRI to predict 
tumor response before the onset of neoadjuvant treatment. Thirty patients underwent DCE-
MRI before and after neoadjuvant chemoradiotherapy. Several kinetic parameters were 
derived from the time-enhancement curves both before and after therapy, and their relative 
difference between pre- and post-therapy was calculated. Only the parameter ‘late slope’ 
measured before the onset of therapy could predict a good response (tumor regression 
grade 1-2) with a sensitivity of 92% and specificity of 82%. 
In Chapter 7 the macroscopic and microscopic parameters of the mesorectal vasculature 
before therapy and its relation to tumor response is investigated. This showed that the 
macroscopic vasculature was enhanced in the mesorectum adjacent to the tumor compared 
to mesorectal vasculature surrounding the normal rectal wall. Macrovasculature was also 
enhanced in node-positive disease compared to node-negative patients. Furthermore, good 
responders showed an enhanced macroscopic vasculature compared to poor responders. 
Thus, DCE-MRI shows a potential for response prediction, but further validation in larger 
patient cohort is warranted to confirm the diagnostic value.
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De doelstellingen van deze thesis waren het evalueren van de oncologische uitkomst van 
orgaan-preservering als behandeling van het rectumcarcinoom, onderzoeken op welke 
manier de patiënten selectie verbeterd kan worden met behulp van moderne MRI technieken 
en het evalueren van de potentie van een nieuwe MRI techniek ter voorspelling van de 
respons voorafgaand aan de start van de therapie.
DEEL I: Orgaan-preservatie
In hoofdstuk 2 werden de oncologische resultaten van onze eerste veelbelovende studie 
onderzocht in een groter cohort. Het tweede doel was het updaten van de selectie en 
inclusie criteria. De selectie van patiënten werd verricht door middel van een rectaal toucher, 
endoscopie en state-of-the-art MRI. Patiënten met een klinisch complete respons werden 
geïncludeerd in het ‘watch-and-wait’ stramien. Patiënten met een bijna klinisch complete 
respons werden 3 opties aangeboden: standaard operatie, TEM of een tweede beoordeling 
na 3 maanden. Honderd patiënten werden geïncludeerd in een orgaan-preserverende 
behandeling; watch-and-wait (n=85) of een TEM (n=15). De mediane duur van opvolgen was 
38 maanden. Vijftien patiënten kregen een lokale teruggroei (allen binnen 25 maanden), 
welke in alle gevallen nog geopereerd konden worden. Vijf patiënten hadden metastasen 
op afstand en vier patiënten zijn overleden. Drie-jaars lokale teruggroei-vrije overleving was 
84% en de totale overleving was 96%. Slechts één van de 22 ondervraagde patiënten uit de 
watch-and-wait groep, had last van ernstige incontinentie. Derhalve is orgaan-preservatie 
een oncologisch veilige optie voor geselecteerde patiënten met een rectumcarcinoom.
DEEL II: Respons evaluatie na therapie
Hoofdstuk 3 geeft een overzicht van de beschikbare literatuur over tumor grootte en 
volume metingen gebaseerd op standaard T2-gewogen MRI voor respons evaluatie na 
chemoradiotherapie. Uit dit overzicht werden grootte- en volume-afkapwaardes afgeleid, 
welke vervolgens prospectief werden gevalideerd in een multicenter cohort waarmee 
de optimale afkapwaarden werden geïdentificeerd. In totaal waren er 14 artikelen die 3 
verschillende meetmethodes (lengte, 3D-grootte en totaal volume) en 3 verschillende 
uitkomstmaten gebruikten (complete tumor respons, tumor regressie graad 1-2 en tumor-
downstaging). Tumor lengte en 3D-grootte bleken niet behulpzaam voor tumor respons 
evaluatie. Totale volume metingen waren veelbelovend, met name voor het evalueren van 
een complete tumor respons met een accuratesse tot 80%. Echter, aangezien de sensitiviteit 
laag bleef (14-21%) lijkt de applicatie in de dagelijkse praktijk beperkt.
Hoofdstuk 4 onderzoekt het potentieel van de nieuwe MRI techniek “magnetization 
transfer” (MT) imaging voor het differentiëren van resttumor en fibrose na neoadjuvante 
chemoradiotherapie. ‘Regions-of-interest’ werden gemeten op de MT beelden en gecorreleerd 
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met de histopathologie. Dit toonde een significant hogere MT ratio in regio’s met fibrose 
(38%) vergeleken met resttumor (30%, p<0.001). De sensitiviteit en specificiteit waren 88% en 
90% voor het detecteren van fibrose met MT. Derhalve zou MT imaging veelbelovend kunnen 
zijn om te differentiëren tussen fibrose en resttumor.
In hoofdstuk 5 hebben we de waarde van MT imaging geëvalueerd om te differentiëren tussen 
patiënten met een goede en een slechte respons na neoadjuvante therapie. De gemiddelde 
MT ratio toonde een AUC van 0.65 en 0.87 voor twee observanten. Echter, de 95e percentiel 
van de MT ratio toonde een AUC van 0.75-0.88 met een goede interobservant overeenkomst 
(ICC 0.80). Magnetization transfer imaging lijkt een veelbelovende modaliteit, maar verder 
onderzoek in een grotere patiëntengroep is nodig.
DEEL III: respons predictie vooraf aan therapie
Hoofdstuk 6 richt zich op ‘dynamic contrast enhanced’ (DCE) MRI voor het voorspellen van 
de tumor respons voorafgaand aan de start van neoadjuvante therapie. Dertig patiënten 
kregen DCE-MRI voorafgaand en na de neoadjuvante chemoradiotherapie. Een aantal 
kinetische parameters werden afgeleid van de ‘time-enhancement’ curves zowel vooraf als 
na de therapie en het relatieve verschil tussen pre- en post-therapie werd berekend. Enkel 
de parameter ‘late slope’ gemeten vooraf aan de therapie, kon een goede respons (TRG 1-2) 
voorspellen met een sensitiviteit van 92% en specificiteit van 82%.
In hoofdstuk 7 werden de macroscopische en microscopische parameters van de mesorectale 
vasculatuur vooraf aan therapie onderzocht, en hun relatie tot de tumor respons. Dit toonde 
dat the macroscopische vasculatuur was toegenomen in het mesorectum rondom de tumor 
vergeleken met het mesorectum rondom de normale rectum wand. Macrovasculatuur 
was ook toegenomen in klier-positieve ziekte vergeleken met klier-negatieve patiënten. 
Daarbij hadden goede responders toegenomen macrovasculatuur vergeleken met slechte 
responders. Dus, DCE-MRI heeft potentieel voor het respons predictie, maar verdere validatie 
in een grotere patiëntengroep is nodig om de diagnostische waarde vast te stellen.
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En dan natuurlijk nog het gedeelte dat het meeste gelezen wordt. Zo niet, het enige deel dat 
gelezen wordt: het dankwoord. En uiteraard ga ik ook mensen vergeten te noemen, anders 
zou het geen echt dankwoord zijn. Maar sorry daarvoor alvast. 
Allereerst wil ik graag alle patiënten bedanken die aan dit onderzoek hebben meegewerkt. 
Zonder jullie bereidwilligheid had deze thesis nooit tot stand kunnen komen. 
Prof. Dr. Regina Beets-Tan, beste Regina, jouw enthousiasme en passie voor dit onderzoek 
is onuitputtelijk. Ik was meteen overtuigd dat ik op de goede plek was beland en ik werd 
al snel opgenomen in het ‘recteam’. Ik heb zeer veel respect voor je hoe je alles weet te 
managen ondanks je drukke schema, maar toch altijd ergens de tijd vindt om snel en kritisch 
naar papers te kijken. Je wist me niet te overtuigen om radioloog te worden (ondanks je 
vele pogingen), maar ik heb wel enorm veel van je geleerd. Bedankt voor de kansen die 
me hebt gegeven en je vertrouwen. Je bent zelf net aan een nieuwe uitdaging begonnen in 
Amsterdam, heel veel succes!
Prof. Dr. Geerard Beets, beste Geerard, ik vind het een eer dat ik deel heb mogen uitmaken 
van het ‘wait-and-see’ project, recent omgedoopt tot ‘watch-and-wait’. Heel bijzonder hoe jij 
je als chirurg hard maakt om patiënten niet te opereren. Ook bij jou kon ik altijd aankloppen, 
wel met het risico dat ik met nog meer nieuwe (soms wilde) ideeën en projecten weer vertrok. 
Bedankt voor je begeleiding en veel succes in Amsterdam.
Dr. Doenja Lambregts, beste Doenja, toen je zelf nog officieel moest promoveren, bleek al 
snel dat je een uitstekende begeleider was. Altijd snel en kritisch naar papers kijken, maar 
ook gewoon een gezellige collega. Gelukkig kon ik jou ook af en toe helpen, door bomen 
van drieën te onderscheiden bijvoorbeeld. Heel erg bedankt voor je goede en prettige 
begeleiding. Ook jij veel succes in Amsterdam!
Prof. Dr. Jos van Engelshoven, het is een eer dat u voorzitterschap van mijn 
beoordelingscommissie op zich heeft willen nemen. Ik wil u en de andere leden van de 
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scheelt maar één dag! (ok, en een jaar…) Je was nooit te beroerd om eens bij te springen en 
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Ik wil het personeel van de radiologie balie en planning bedanken, met in het bijzonder 
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De afdeling chirurgie, met in het bijzonder de GE-chirurgen (Laurents Stassen, Marjolein 
Smidt, Kristien Keymeulen, Stephanie Breukink, Jarno Melenhorst), bedankt voor jullie inzet 
om de patiënten te begeleiden in het wait-and-see traject. Marjolein wil ik tevens bedanken 
voor  je enthousiasme en passie voor je vak en onderzoek waarmee je mij hebt aangestoken 
toen ik als student voor je deur stond. 
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